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CHAPTER I
INTRODUCTION

Adipocytes are highly specialized cells that play a central role in systemic
energy homeostasis. These cells have evolved complex biochemical machinery
and transport systems that allow them to store energy in the form of
triglycerides in times of nutritional abundance, and release this energy in times
of nutritional deprivation. Intensive studies of adipocyte biochemistry have
revealed considerable information about the hormonal control of carbohydrate
and lipid metabolism, particularly the hormone-regulated enzymes involved in
these processes (1). Despite that, our understanding of how adipocytes
differentiate and the precise role these cells play in maintaining blood glucose
homeostasis is still incomplete.
When the function of adipocytes is altered, a number of disease states occur
including cachexia, lipodystrophy, obesities, and diabetes (2-4). In the latter
state, insufficient disposal of glucose by adipose and muscle leads to elevated
blood glucose levels. This hyperglycemic state can be corrected in diabetic
patients by treatment with oral hypoglycemic agents which have been mostly
shown to increase glucose uptake by stimulating insulin release from the
pancreas (5). A more recent and favorable approach is to use insulinsensitizers, agents that act to enhance sensitivity of target tissues to insulin.
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Our preliminary studies with pioglitazone, a novel hypoglycemic agent which
presumably acts to enhance insulin sensitivity of target tissues (6), suggested
that this agent might act to accelerate adipocyte differentiation.
Adipocyte cells express a program of proteins quite distinctive from other
cell types, thus determining the ability of these cells to carry out their
specialized function in energy balance (7-10). It is known that the acquisition of
specialized phenotype, which characterizes the latter stages of differentiation of
cells and tissues, is associated with the coordinate expression of new genes and
the concomitant loss of expression of genes specific to less-differentiated cells.
We therefore, sought to fully investigate the effect of pioglitazone on cell
differentiation to determine how such an effect might contribute to the action of
pioglitazone to regulate cellular glucose uptake.

CHAPTER II
REVIEW OF REI.ATED LITERATURE

Glucose Transpoit in theAdipocyte
Adipose tissue serves as the primary energy reservoir in mammals, converting
excess dietary glucose and fatty acids into triglycerides. When dietary nutrients
are lacking, these triglycerides are hydrolyzed to glycerol and fatty acids and
released into the systemic circulation. It is estimated that adipose tissue
accounts quantitatively for 10-30% of whole-body glucose metabolism (11).
The transport of glucose into muscle and adipose tissue, the rate limiting
step of glucose utilization, is mediated by integral membrane carrier proteins
belonging to a family of facilitated glucose transporters (12, 13). These proteins
transport glucose down its concentration gradient by facilitative diffusion, a
passive, energy independent process that is tightly regulated in adipocytes by
insulin and counterregulatory factors (1).

Stimulatory actions of insulin on ~lucose transport
The process by which insulin increases glucose transport in peripheral tissues
has been studied extensively. Insulin actions are initiated by binding of the
hormone to a specific membrane receptor that possesses an intrinsic protein
kinase activity localized to its transmembrane B-subunit (14).
Autophosphorylation of the receptor on tyrosine residues results in receptor
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activation with subsequent stimulation of glucose transport (15,16). At least two
members of the glucose transporter family (GLUTl and GLUT4) are
expressed in both adipose and muscle, tissues where glucose uptake is sensitive
to regulation by insulin (17). It was demonstrated that adipocytes contain a
large intracellular pool of glucose transporters. Insulin stimulates glucose
uptake primarily by induction of a rapid translocation of pre-existing
transporters from an inner membrane fraction to the plasma membrane
resulting in as much as a 100-fold increase in the Vmax for transport (18,19).
Although both GLUTl and GLUT4 transporters are capable of translocation,
the GLUTl protein accounts for about 10-fold fewer glucose transporters than
GLUT4 protein in primary adipocytes, and these GLUTl transporters are
mostly localized in the plasma membrane. Thus, the effect of insulin appeared
to be predominantly on the GLUT4 protein (20,21). Since quantitative
comparisons revealed a significant discrepancy between the transport activity
and the number of transporters in basal and insulin-stimulated cells, it was
suggested that other mechanisms such as changes of the transporter intrinsic
activity also contribute to insulin action (19,22-24). Indeed, qualitative
alternations of the glucose transporters were reported, including GLUT4
phosphorylation in adipocytes treated with .B-adrenergic agonists (25), or with
agents that increased intracellular calcium levels (26). In addition to these
acute effects, prolonged insulin treatment further regulated transport activity by
a process requiring ongoing protein synthesis that may involve increased glucose
transporter gene expression (17,27).
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Inhibitmy actions of counterregulatmy factors on glucose transport
The actions of insulin are opposed by several counterregulatory factors
including hormones, neurotransmitters, and metabolic substrates (2,28).
Glucagon, the most potent counterregulatory hormone, acts mainly on liver, but
it does not affect peripheral glucose metabolism (1). In adipocytes, it was
shown that stimulators of lipolysis are inhibitors of insulin-stimulated glucose
oxidation and by inference, inhibitors of glucose transport (29). Conversely,
antilipolytic agents exert an opposite effect, and produce a moderate
augmentation of the insulin-stimulated transport activity (29). In rat adipocyte
cells, ligands such as catecholamines stimulate adenylate cyclase leading to
elevated cellular cAMP levels and inhibition of insulin-stimulated glucose
transport activity (30,31). Similarly, the adenylate cyclase inhibitors such as
prostaglandin E 1· nicotinic acid, and non-metabolized adenosine analogues
prevent or reverse this inhibition (32). The inhibitory effect of catecholamines
in adipocytes reflects both a shift of the concentration-response curve to higher
insulin concentrations and a marked reduction of the maximal effect on insulin.
The first component may be attributed to inhibition of the insulin receptor
kinase, whereas the latter effect appears to reflect a change in intrinsic activity
of glucose transporters. In addition, the insulin-induced subcellular
translocation of glucose transporters is decreased in cells that have been
exposed to ambient levels of cAMP. In contrast to these findings, activation of
the lipolytic system in human fat cells at the levels of adrenoreceptors,
adenylate cyclase, or protein kinase appears to be associated with an
acceleration of the glucose transport rate (29). This indicates that there are
important species differences in the regulation of adipocyte glucose transport at
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least regarding the effect of lipolytic agents. On the other hand, the action of
antilipolytic agents (ie. insulin and adenylate cyclase inhibitors) appear to be
similar in human and rat fat cells (29).
Two additional hormones that are known to modulate the regulation of
glucose transport by insulin in the rat adipose cells are the glucocorticoids (33)
and growth hormone (34 ). It has been established that glucocorticoids,
specifically the analogue dexamethasone, induce a decrease in both basal and
insulin-stimulated glucose transport activity (35) either by accelerating
degradation of glucose transporters present in the plasma membrane and/ or by
inducing a redistribution of glucose transporters in favor of the intracellular
pool. An excess of circulating growth hormone in both rat and man appears to
correlate with insulin resistance and elevated blood glucose levels, while growth
hormone-deficient conditions are associated with an increased response to
insulin (19); the cellular mechanism underlying this phenomenon has not been
established.
Forskolin, an agent known to elevate cellular cAMP levels, is another
powerful inhibitor of glucose transport in adipocytes; this agent initiates
adenylate cyclase stimulation and inhibit glucose transport at different sites
including direct binding to glucose transporters (36). Inhibitors of nucleoside
transport (methylxanthines) are also potent inhibitors of glucose transport in rat
adipocytes, apparently by direct interaction with the glucose transporters (36).
Finally, metabolic substrates such as glucose and amino acids have profound
effects on modulating insulin's stimulatory actions on glucose uptake in primary
cultured adipocytes (37). Specifically, circulating levels of glucose and amino
acids modulate cellular metabolism through two independent, but integrated,
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control systems. The first system is the classical substrate-pancreatic axis, in
which glucose and amino acids act as potent secretagogues for the release of
insulin. The second control system acts in tandem with the first by enabling
insulin target tissues to continuously monitor circulating levels of glucose and
amino acids, thereby modulating cellular responsiveness at distinct postreceptor
sites within the insulin action pathways. It was recently discovered in the rat
primary cultured adipocytes that routing of incoming glucose through the
hexosamine biosynthesis pathway leads over several hours to a refractory state
in which the ability of insulin to stimulate glucose uptake is severely impaired- a
state known as insulin resistance. Glutamine:fructose-6-phosphate
amidotransferase was also found to play a central role in the development of
insulin resistance, as this enzyme catalyzes the first and limiting step in the
formation of hexosamine products (37).

Adipocyte Differentiation
Adipocyte differentiation occurs through a process in which preadipocyte
cells, ie. fibroblasts cells populating the future adipose tissues, are
reprogrammed to stop dividing and start expressing properties and functions of
adipocytes. While the reprogramming process generating committed cells takes
place only in embryonic life, the differentiation of these committed cells can
take place at any time, even in adult life (38).

Models for studying the adipocyte
Since primary adipocytes isolated from adipose tissue only remain viable a
few hours, the ability to study adipocyte differentiation, gene expression, and
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morphological and biochemical changes during the process, was greatly
facilitated by the isolation of preadipocyte cell lines that could be induced to
differentiate into adipocytes in culture. Studies showed that Swiss 3T3
fibroblasts were able to differentiate spontaneously to adipocytes in culture
(39). This process took 2-4 weeks, and the percentage of differentiated cells
varied from culture to culture. From these established fibroblasts, Green and
Kehinde isolated clonal sublines (e.g. 3T3-L1 and 3T3-F442A) that could
differentiate to adipocytes at high frequency (40,41). Also established were
clonal cell lines ob17 and HG-Fu rising from differentiated adipocytes from the
epididymal fat pad of adult ob/ ob mouse, PFC6 from the stromal-vascular
fraction of epididymal fat pad which contains preadipocyte cells, and the ST13
cell line arising from the parental line ST that was itself established from a
mammary carcinoma of the ddN mice (42).
Such differentiation was studied extensively and was found in many respects
to resemble the in vivo development of adipocytes from stromal vascular cells
(the adipose precursor cells). In these cell lines, the preadipocytes are
fibroblast-like cells. Once the cell growth was arrested by reaching confluence
in culture, the cells exhibited morphological characteristics of adipocytes and
accumulated lipid droplets. At the same time, the cells developed enzymatic
activities related to fatty acid and triglyceride synthesis (43), and acquired
sensitivities to hormones that are important in the regulation of fat and
carbohydrate metabolism (44,45).
Under ordinary conditions, only a minority of the cells undergo adipose
differentiation. There is therefore a marked heterogeneity in the predisposition
for differentiation. This property of preadipose cells ensures that some cells are
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retained in developing tissue for later recruitment to formation of more adipose
cells (38).

Mitogenic response of differentiating cells and its role in clonal selection
It is known that for preadipocytes, as well as other cell types, growth arrest is

a prerequisite for the induction of the differentiation program (46).
Paradoxically, among the earliest events taking place in adipocyte
differentiation was a mitogenic response in susceptible cells so that they
appeared later in clusters (46-48). Studies have shown that after stimulation
with adipogenic serum, 3T3-F442A preadipocyte cells underwent a mitogenic
response characterized by a burst in DNA replication and cell division before
they expressed the differentiated state. In addition, it was demonstrated that
DNA synthesis was required for adipose differentiation of cultured cells (48).
Growth arrest at the Gi/S boundary triggered the activation of early genes.
But the expression of late markers, which led to terminal differentiation and
accumulation of neutral lipids, took place after a limited number of mitoses of
early-marker-expressing cells. The mitogenic proliferation of those cells
responding to the adipogenic factor led to a selective increase in their progeny,
all of which formed adipocytes (49). This form of mitogenic response occurred
only in the early stages of adipocyte differentiation since fully differentiated
cells do not divide (38).

Morpholo~cal

changes during adipocyte differentiation

Differentiation of preadipocytes into adipocytes is accompanied by changes
in their morphological appearance. Preadipocytes appear as extended irregular
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fibroblast-like cells. Upon differentiation, such cells enlarge, acquire a
spherical shape, and later accumulate lipid droplets in their cytoplasm. Small
lipid globules may ultimately fuse into a few or a single fat globule. It was
shown that the change in cell shape during differentiation was independent of
lipid accumulation. This was demonstrated by culturing cells in biotin-deficient
medium wherein the cells were unable to synthesize fatty acids and were
therefore unable to accumulate triglycerides (50). Nevertheless, these cells
acquired a spherical shape, suggesting that the morphological changes were part
of the differentiation program and not simply the result of triglyceride
accumulation in their cytoplasm. Measured changes of the synthesis and
assembly of cytoskeletal proteins during differentiation were consistent with
that concept. Undifferentiated 3T3-Ll cells, for instance, contained actin-like
stress fibers and synthesized actin as well as bundles of intermediate filaments
(51). Upon differentiation, both structures disappeared and cell content of
actin and tubulin decreased several fold. A decrease in the net production of
extracellular matrix components, particularly proteoglycans typical of fibrous
connective tissue, was also described (52).

Enzymatic changes and triglyceride accumulation during differentiation
During adipocyte differentiation, there is a large increase in the synthesis of
more than 50 cellular proteins (7) and a 50- to 100-fold increase in the cellular
triglyceride content (40). Triglyceride accumulation can be affected by different
factors, which make it an extremely variable feature. Insulin, methyl isobutyl
xanthine and dexamethasone were shown to increase, while B-adrenergic
catecholamines decrease, triglyceride accumulation (38,40). A coordinate rise
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in most of the enzymes of de novo fatty acid synthesis (53) and of some of the
enzymes of the triglyceride synthesis pathway was observed (43,54 ). This greatly
enhanced the ability of cells to synthesize fatty acids, to take up exogenous fatty
acids, and to esterify fatty acids obtained from either source (55,56); all of these
actions resulted from increased expression of appropriate regulatory enzymes.

Chanies in receptor levels and hormonal responses of differentiated cells
Although preadipocyte cells in culture possess cell surface receptors for
insulin, no metabolic responses to insulin are observed in these cells. Upon
differentiation, there is a dramatic increase in the insulin-binding capacity (57)
which is primarily accounted for by a change in receptor number resulting from
a parallel rise in the rate of insulin receptor synthesis (44,45). These changes in
receptor levels were accompanied by increases in glucose metabolism and
insulin responsiveness (58-60), the latter of which was shown to be due to a
decreased basal glucose transport rate rather than an increased maximal rate
after stimulation by insulin. The coupling between insulin binding and the
biological response was greatly enhanced, as was the coupling to adenylate
cyclase in response to ACTH and B-adrenergic catecholamines (7,38,61). In
addition, adipocytes differentiated from different cell lines manifest properties
similar to adipocytes isolated from adipose tissue, including responsiveness to
lipolytic hormones, elevated basal glucose transport activity after prolonged
exposure to insulin (62), and resistance to stimulation by insulin after chronic
exposure to insulin, glucocorticoids (7), and growth hormone (63).

12
Factors That Regulate Adipocyte Diffeientiation

The specific factors that regulate adipocyte differentiation and the
mechanisms by which such factors act have not been revealed. Initially, cells
have to be committed for differentiation. Evidence of the process whereby
committed cells were generated resulted from the experiment in which cells of
the nondifferentiating mouse 3T3-C2 line were transfected with DNA from
uninduced 3T3-F442A preadipocytes or from human fat tissue (64). Such
transfection permitted recovery of 3T3-C2 transfectants that differentiate into
adipocytes in the presence of insulin, thus implicating the presence of
transregulatory gene or genes in committed 3T3-F442A or human fat cell DNA
that was sufficient to commit 3T3-C2 cells to adipocyte differentiation. In order
for preadipocytes to subsequently differentiate, the cells must reach a confluent
resting state that is followed by a mitogenic response (46). However, growth
arrest itself was not sufficient to induce differentiation, since agents such as
sodium pyruvate that cause growth arrest only accelerated differentiation in the
presence of other adipogenic factors (65). Extracellular and regulatory
adipogenic serum factors of different species were thus shown to be required for
the process which could be divided into early and late stages. Fetal calf serum
is by far the most effective serum used for cellular differentiation (66). In
addition, bovine pituitary extracts showed an adipogenic activity that was at
least three orders of magnitude higher in pituitary than in fetal calf serum. Only
growth hormone was found to promote preadipocyte differentiation, while
adipogenic activity was not associated with other pituitary polypeptides (67). A
number of studies have implicated both growth hormone (GH) and insulin like
growth factor-I (IGF-I) (68-70) during the early events of adipose
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differentiation. Growth hormone is suggested to promote preadipocyte
differentiation, generating committed precursors sensitive to the proliferative
mitogenic action of IGF-1. The late events of the adipose pathway represent the
terminal differentiation of the committed cells, and require the presence of
modulating signals mainly elicited by physiological concentrations of insulin
(43,47). Thus, it seems that a combination of mitogenic-adipogenic signals is
required to trigger terminal differentiation of preadipose cells. The
requirement for serum, however, is not absolute since 1246 cells were able to
differentiate in a serum-free medium containing insulin, transferrin and
fibroblast growth factor (7). Another study demonstrated a complete adipose
differentiation of 3T3-L 1 cells in a chemically defined culture system
supplemented with insulin, glucocorticoids, and factors that increase the cAMP
content of the cells (71), and a third study showed 3T3-Ll differentiation by
IGF-1 and insulin in a serum-free culture system (69). Although the expression
of the adipocyte phenotype has been shown to be under the control of lipogenic
hormones, especially insulin, other factors including indomethasone (60),
prostaglandin F2a and 1-methyl-3-isobutylxanthine (72), dexamethasome
(65,73), triiodothyronine (74), glucocorticoids (75), and other factors such as
RU38486, a potent glucocorticoid and progestin antagonist(76), sodium
pyruvate in combination with insulin or dexamethasone (65), the antidiabetic
agent AD4743 (77,78), or the expression of transfected ras oncogenes (79), have
all been variously shown to accelerate adipose differentiation in adipocyte
models
On the other hand, adipocyte cells may lose their differentiated function and
exhibit properties of less differentiated cells in response to modulation by
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environmental influences. Cultured TAl adipocytes treated with tumor
necrosis factor alpha (TNF a) for instance, lose intracytoplasmic lipid and, over
a period of days, come to resemble their predifferentiated progenitors (80).
Within hours of TNF addition to adipocytes, mRNAs for genes whose
expression is augmented during adipogenesis decreased to predifferentiated
levels. Transforming growth factor-B also caused a rapid decrease in expression
of adipose genes when added to fully differentiated cells (80,81 ), while
interferon completely inhibited the differentiation of 3T3-Ll mouse fibroblasts
into adipocytes (82).

Mechanisms Underlying Activity Changes During DHerentiation
The acquisition by adipose precursor cells of the morphological and
biochemical characteristics of mature adipocytes is mediated by extensive
reprogramming of gene expression resulting in alternations in the abundance of
several mRNAs and proteins, and appearance of many new adipocyte-specific
mRNAs and proteins. These changes are brought about by both transcriptional
regulation at the level of the gene and post-transcriptional regulation between
the RNA and the protein product (83-85).

Expression of adipocyte-specific genes
Electrophoretic studies of preadipocyte and adipocyte proteins indicated that
there were major quantitative changes in at least 100 protein species and that
40% of the soluble adipocyte proteins represented newly produced material
(83,86) including enzymes involved in fatty acid and triglyceride synthesis, such
as glycerol phosphate dehydrogenase (GPDH), fatty acid synthetase,
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phosphoenol pyruvate carboxykinase, and lipoprotein lipase (7,56). Adipocyte
differentiation was later shown to be associated with the coordinate expression
of new genes and the concomitant loss of expression of genes specific to lessdifferentiated cells (8-10,73). Subsequently, new and potentially important gene
products of the adipocyte were identified by isolating cDNA clones
corresponding to mRNAs that are specifically induced during adipocyte
differentiation (84,85). Included are the cDNA clones encoding GPDH, a key
enzyme in triglyceride synthesis which provides the glycerolphosphate backbone
for acylation and its protein accounts for about 2% of the soluble protein in the
adipose 3T3 cells, the adipocyte fatty acid-binding protein, aP2, that accounts
for about 6% of soluble protein in the adipose cells, and the adipocyte serine
protease homolog, adipsin, that accounts for about 5% of the soluble protein of
adipose cells (85). The following section will discuss some of these genes, which
are also known to be involved in energy metabolism.

The aP2 gene
The gene encodes an adipocyte homologue of myelin P2. This protein
accounts for about 6% of adipocyte soluble proteins and has sequence
homology to a class of fatty acid-binding proteins that includes liver fatty acid
binding protein, intestinal heart fatty acid-binding protein and cellular retinoic
acid-binding protein (87,88). The precise function of this putative lipid carrier
protein is unknown, although it was found to be a cellular target for
phosphorylation by the insulin receptor tyrosine kinase, and may thus be
considered a potential mediator of insulin actions (89-91). The abundance of
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aP2 mRNA is increased by a factor of at least 100 during adipocyte
differentiation (92).

The adipsin gene
This gene encodes an adipocyte-specific serine protease homolog with
complement factor D activity, formerly called 28k, that is synthesized by
adipocytes and secreted into the blood stream (93-95). Its protein accounts for
about 5% of the adipocyte soluble proteins. The expression of this gene was
found to be quantitatively altered in certain models of obesity and diabetes (9698). Adipsin mRNA abundance is increased in adipose tissue during fasting in
normal rats and in diabetes due to streptozotocin-induced insulin deficiency, but
its mRNA abundance is decreased during the continuous infusion of glucose,
which induces a hyperglycemic, hyperinsulinemic state that is accompanied by
an increased adipose mass. Adipsin mRNA expression is also suppressed

( > 100-fold) in two strains of genetically obese mice (dbl db and obi ob), and in
obesity chemically induced by injection of monosodium glutamate into newborn
mice. Circulating adipsin protein is correspondingly decreased in these animal
models of obesity (98).
Adipsin mRNA has also been shown to increase over 100-fold during
differentiation of 3T3-preadipocytes (85,99). Studies have shown that insulin
markedly increases adipsin secretion and mRNA levels during differentiation,
presumably due to the ability of insulin to stimulate differentiation (100). This
is in contrast with the finding of another study in which cells were differentiated
in serum deprived-medium. These cells already exhibit, at day 1, a maximal
amount of mRNA encoding for adipsin, which is tenfold decreased by the
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presence of insulin (73). Both studies however, demonstrated negative effects
of insulin on the abundance of adipsin mRNA and secretion in mature
adipocyte cells. These findings indicate that adipsin appears to be an early
marker of adipocyte differentiation, and its gene expression is increased during
differentiation, but is dramatically down-regulated by the presence of insulin,
especially after differentiation (73, 100).

The insulin receptor gene
This gene encodes the insulin receptor which mediates actions of insulin in
target cells, presumably through the activation of the receptor tyrosine kinase
(15, 101). Although insulin receptor is a housekeeping protein that is essential
for cell growth and is usually synthesized at low levels in all cells, there are
increased numbers of insulin receptors in major target tissues for insulin such as
liver, muscle, and adipocytes. In addition, the number of insulin receptors
decreases considerably under certain conditions, ie., chronic exposure of cells to
insulin leads to a net loss of receptors from cell surface (down-regulation) by
decreasing biosynthesis and accelerating degradation (58). In contrast,
differentiation of 3T3-preadipocytes leads to a 10- to 20-fold increase in the
number of insulin receptors on the cell surface, and this change is paralleled by
a 10-fold increase in insulin receptor mRNA transcripts of two sizes (57,59, 102).
Prolonged incubation of 3T3-L 1 differentiated adipocytes with insulin however,
does not induce hormone-mediated down-regulation of the receptor (44 ).
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Glucose transporter genes
Glucose uptake across plasma membrane of insulin-sensitive tissues (heart,
skeletal muscle and adipose) is carried out mainly by means of two transporters
(20) belonging to a family of at least five tissue-specific facilitated-diffusion
proteins (12,13,103-105). GLUT4 is an insulin-responsive glucose transporter
expressed exclusively in fat and muscle (106); GLUTl is a transporter for basal
uptake of glucose that is expressed ubiquitously in most tissues. The rate of
glucose uptake is subject to both short-term and long-term regulation. It has
been shown that insulin acutely, ie. within minutes, increases glucose uptake 10to 20-fold via the redistribution of glucose transporters from an intracellular
pool to the plasma membrane (20, 107). After hours of treatment with insulin,
there is a further increase in glucose uptake, which requires ongoing protein
synthesis and may be mediated by an increase in glucose transporter gene
expression (108). Other examples of long-term alternations in the
responsiveness of glucose uptake to insulin include the fasted and diabetic
states, both of which are associated with a decrease in GLUT4 mRNA and
protein (109), and the differentiation of preadipocyte cells. It was demonstrated
that undifferentiated 3T3-Ll and 3T3-F442A preadipocytes express only
GLUTl transporter mainly on the cell surface, and are unresponsive to insulin
(110). Upon differentiation, a large intracellular pool of glucose transporters is
formed by redistribution of GLUTl and by addition of newly synthesized
GLUTl and GLUT4 transporter into this pool (61,111), contributing to the
development of insulin sensitivity in the differentiated cells (61). Once
differentiated, 3T3 adipocytes display properties similar to adipocytes from fat
tissue with regard to short and long term regulatory effects on glucose transport.
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Such cells respond to acute insulin treatment with increases in glucose transport
above basal levels (61). Both GLUTl and GLUT4 appeared to be hormonesensitive, since in differentiated cells insulin gave rise to transporter
translocation from the intracellular compartment to the plasma membrane.
Chronic-insulin treatment has been shown to produce an increase in the mRNA
and total protein for GLUTl (108). The expression of GLUTl is associated
with an increase in basal glucose uptake, but not in the insulin-stimulated
increase in 2-deoxyglucose uptake rates by 3T3-L 1 fibroblasts and adipocytes
(112). However, no change was observed in the total cellular mRNA and
protein for GLUT4, although availability of GLUT4 at the cell surface was
down-regulated to half the level found in the acute treatment (62).
Differentiated 3T3 adipocytes, however, differ from those cells isolated from fat
tissue with regard to the relative abundance of their glucose transporter
isoforms. GLUT4 protein in fat tissue adipocytes is expressed at a considerably
higher levels than is GLUTl protein. This is reversed in 3T3-Ll adipocytes
where the relative amount is 4 to 1 for GLUTl and GLUT4, respectively (21).
These observations indicate that the translocation of GLUT4 could largely
account for the insulin effect on transport rate, as the case in fat tissue, only if
the intrinsic activity of GLUT4 is much higher than that of GLUTl.

Reirnlation of adipocyte gene expression
The observed coordinate changes in the expression of a group of genes
during differentiation has led to intensive investigation of the mechanisms
underlying such processes. Run-on transcription activity by isolated nuclei
revealed that the large increases in abundance of several mRNAs were
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accompanied by marked rises in their nuclear transcription rates. This was
particularly shown for highly regulated mRNAs (20- to 100- fold increase in the
steady-state mRNA levels) such as those encoding aP2 (8,9), adipsin (9),
glycerol phosphate dehydrogenase (9), and phosphoenolpyruvate carboxykinase
(56), thus suggesting that an increased rate of specific transcription is primarily
responsible for the accumulation of these mRNAs during differentiation. The
activation of transcription of those adipocyte-specific genes was not synchronous
indicating that the temporal differences in the appearance of different adipocyte
mRNAs probably result from differences in the times of activation of
transcription (9). However, no changes in the rates of transcription was
observed for moderately regulated mRNAs (2- to 4- fold increase or decrease in
their steady state mRNA levels) such as fructose-1,6-bisphosphate aldolase,
actin and tubulin mRNAs (8). These same studies indicated that posttranscriptional regulatory mechanisms were operative during differentiation of
adipose precursor cells. This was inferred from the poor correlation between
relative steady-state mRNA levels and transcription rates for some of the genes.
Steady-state levels of mRNAs for aP2 and adipsin for instance, were much
greater than would be expected from their relative transcription rates,
indicating a possible role for regulation of mRNA stability (84 ).
A search for candidate transcription factor(s) or regulatory sequence
element(s) that could be involved in coordinating those observed changes in
gene expression revealed several different possible mechanisms. DNase I
footprinting for promoters of several adipocyte-specific genes using nuclear
extracts from undifferentiated and differentiated 3T3-L 1 cells revealed that a
differentiation-specific nuclear factor binds to specific regions relative to the
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start site of transcription. This transcription factor was later shown to be the
CCAAT/enhancer binding protein (C/EBP), the mRNA of which was found at
high levels in tissues that metabolize lipids and cholestrol-related compounds,
mainly liver and adipocytes (113,114), and its expression was limited to fully
differentiated fat and liver cells. Transient cotransfection studies revealed that
C/EBP binds to, and trans-activates promoters of several differentiationdependent genes, including GLUT4 (115), aP2, stearoyl-CoA desaturase 1
(116,117), and insulin receptor (118) gene promoters, as well as the C/EBP
promoter itself (119). Hence, it was proposed that C/EBP may play a key role
in coordinating transcription of genes involved in energy metabolism during
differentiation of adipocytes (120,121). Consistent with this proposed role is the
observation that an increase in the rate of C/EBP transcription precedes that of
several adipose-specific genes whose promoters are transactivated by C/EBP
(122).
On the other hand, a comparison of the DNA sequences 5' to the
transcription start site of several differentiation-dependent genes allowed
characterization of sequence homologies which might represent core elements
involved in differentiation-dependent transcription. Two such elements,
designated fat-specific elements FSE 1 and 2, were described (92, 123). These
elements are FSEl, a 14-base sequence present in multiple nonidentical copies
in the 5' flanking region of GPDH, aP2, and adipsin, and FSE2, a 21-base
sequence present in a single copy in the 5' flanking regions of only the GPDH
and aP2 genes that acts as a negative regulator in preadipocytes (92, 123). The
gel mobility shift assay indicated that Fos, a nuclear phosphoprotein encoded by
the c.fos proto-oncogene, is a major component of a protein complex that binds
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the FSE2 element in a differentiation-dependent manner (124). This was
demonstrated by the ability of antibodies to F os to disrupt specific binding of
factors to the FSE2 sequence but not to factor-binding sequences from several
other genes (124). Within the aP2 FSE2 sequence, Fos complexes bind DNA
containing the sequence TGACTCA, previously identified as the consensus
sequence for the binding of mammalian transcription factor AP-1 and yeast
transcription factor GCN4 (125). Consistent with the suggested regulatory role
for FSE2 is the observation that Fos complex exerts a negative regulatory effect
on aP2 gene expression in undifferentiated 3T3-F442A cells. Another study
showed that at least two distinct sequence elements in the aP2 promoter
contribute to the expression of chimeric gene in transfection assays (126). An
AP-1 site shown to bind to Jun- and Fos-like proteins, serve as a positive
regulator of gene expression in adipocytes only, and C/EBP binding sequences
upstream to the AP-1 site can stimulate expression in fat cells in the intact aP2
promoter. This indicates that sequences which bind C/EBP and the Fos-Jun
complex play major roles in the expression of the aP2 gene during adipocyte
differentiation (126). However, recent evidence using a series of transgenic
mice containing 5' flanking sequences in the aP2 promoter linked to the
bacterial gene chloramphenicol acetyltransferase demonstrated that the
proximal-promoter binding site for AP-1 and C/EBP were neither sufficient nor
necessary to give adipose-tissue expression in vivo. Rather, an upstream
adipose specific enhancer was required and sufficient for the expression of the
chimeric gene in vivo (127).
Also identified are sequences with homology to the triiodothyronine (T3)
receptor binding site that are present in multiple copies in the regulatory region
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of adipsin, aP2, and GPDH. This is in agreement with the observation that T3
stimulates the differentiation in preadipocyte cell lines and in primary cultures
of stromal vascular cells. In addition, GRE core sequence was identified in the
5' flanking region of the aP2 gene which is probably responsible for the
induction of the aP2 gene by glucocorticoids (75,84). Although several
hormones and transcription factors have been implicated in adipose-specific
gene expression, little is known about sequences responsible for transcriptional
activation by each hormone. The cellular factors that interact with these
hormones to modulate transcription also have not been identified.

Adipocytes and Diabetes
The major depots for whole body glucose disposal are muscle and adipose.
Since insulin is known to facilitate glucose disposal, insufficient glucose disposal
by these tissues can result either from absolute deficiency of insulin as in
insulin-dependent diabetes mellitus (IDDM), or from resistance of target
tissues to insulin as in non-insulin-dependent diabetes mellitus (NIDDM).
Intensive studies were carried out to characterize mechanisms for cell resistance
to insulin. The action of insulin involves many gene products. Target-cell
resistance could therefore be due to defects affecting any protein between the
receptor and the final insulin-regulated proteins (128). Candidate proteins
include the insulin receptor, members of the family of glucose transporter
proteins, several enzymes involved in glucose metabolism such as hexokinase,
and substrates for insulin-receptor kinase or signaling intermediates (129). In
addition, many circulating factors and physiologic states adversely affect the
sensitivity of target tissues to insulin. Insulin resistance for instance, is
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ubiquitous in obese people and in lean or obese patients with non-insulindependent diabetes (NIDDM) (129). Investigation of target-tissue defects in
these states indicated a complex etiology (4, 130) variously involving decreases
in the number of insulin receptors( 131) or impaired insulin receptor
autophosphorylation and tyrosine kinase activity (132), altered expression of
insulin receptor types that are generated by alternative splicing of a primary
gene transcript (133), impairment of insulin-stimulated glucose transport, and
decreases in the number of GLUT4 glucose transporters as well as impairment
of their functional activity in adipocytes of NIDDM and obese subjects (134138).

Oral Hypoglycemic Agents
Early hypoglycemic agents used for the treatment of NIDDM largely
addressed the insulin secretory defects of the disease. In vitro studies have
shown that first generation-sulfonylureas exert a direct and immediate
stimulatory effect on insulin secretion from islet B cells by increasing sensitivity
of islet B cells to the insulin-releasing effect of glucose (5). Sulfonylureas
interact in a specific and saturable manner with a single type of binding site on
the cell plasma membrane (5). The more complex substitutions of secondgeneration sulfonylureas may be responsible for improved anchorage at the
binding site, thus conferring greater insulin-releasing potency. In addition,
sulfonylureas exert extrapancreatic glucose lowering effects mainly directed
towards correcting the defects of glucose metabolism in liver, muscle and fat of
NIDDM patients. However, sulfonylureas alone are ineffective in the control of
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hyperglycemia if insulin is absent, but they increase the hypoglycemic effect of
exogenous insulin (139-142).
A novel class of hypoglycemic agents that are effective in animal models of
NIDDM has recently emerged. Thiazolidinediones including pioglitazone,
ciglitazone, and englitazone, were all shown to lower plasma glucose levels
presumably by enhancing both sensitivity and responsiveness of target tissues to
insulin. Epididymal fat pads removed from obi ob mice treated with ciglitazone
were shown to exhibit increased response to insulin in terms of insulinstimulated glucose oxidation and lipogenesis (143). Such treatment did not
change insulin binding, thus suggesting that these agents act to amplify cellular
responses to insulin at post-receptor level(s). In agreement with this concept
are observations that pioglitazone corrected deficits in glucose transport and
GLUT4 mRNA and protein abundance in fat and, to a lesser extent, muscle
cells of insulin-resistant animals, and that such actions were dependent on the
presence of circulating insulin (6). Pioglitazone was also shown to increase
insulin-stimulated autophosphorylation and kinase activity of the insulin
receptor in muscle cells (144), further supporting the concept that pioglitazone
acts to amplify post-binding steps in the insulin-response cascade.

Proposed studies
Our laboratory has been interested in investigating the mechanism(s) for
insulin resistance in non-insulin-dependent diabetes mellitus, ie. how the
function of muscle and adipose is altered in insulin resistance and what
molecular mechanisms underlie such changes. We are also interested in
probing the action of agents that have the potential of reversing this resistance.
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One such agent, pioglitazone, is a compound that has been identified
empirically for its ability to lower elevated plasma glucose levels in animal
models of NIDDM (145).

Hypothesis
I propose to test the hypothesis that the antidiabetic agent pioglitazone acts
to enhance cellular glucose utilization by promoting differentiation of
preadipocytes to adipocytes, thus inducing expression of genes encoding glucose
transporters and other adipocyte-specific proteins.
In this differentiated state, adipocyte cells are known to be fully active in
glucose uptake, storage, and metabolism.

Specific Aims

To conduct an in vivo animal study of such kind would be complex due to the
simultaneous presence of multiple hormonal factors known to affect adipocyte
differentiation. There is also difficulty in obtaining pure populations of
precursor cells that undergo differentiation under controlled conditions. For
these reasons, the in vitro cell culture model, the 3T3-F442A
preadipocyte/ adipocyte cell line will be used. Since our prior in vivo studies
showed that pioglitazone-enhanced glucose transport activity required the
presence of insulin (6), subsequent studies will be carried out in the presence or
absence of insulin.
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AIM 1

To determine the basis of pioglitazone-mediated acceleration of 3T3
differentiation from fibroblast to adipocytes by examining markers of the
adipogenic pathway and the expression of adipocyte-specific genes.

Experimental Design
1- Examine effects of pioglitazone and/ or insulin treatments on cell morphology
and triglyceride accumulation.
2- Examine effects of pioglitazone and/ or insulin treatments during
differentiation on glucose transport activity and glucose transporter gene
expression (GLUTl and GLUT4) at mRNA and protein levels.
3- Assess effects of pioglitazone and/ or insulin treatments on differentiationrelated gene expression of adipocyte-specific genes ( aP2, adipsin, insulin
receptor) at the mRNA level.
4- Since insulin has been reported to down-regulate some messages after
differentiation, mRNA abundance in some cases will be assessed after the
removal of the differentiation inducer (insulin or pioglitazone) to rule out such
effect.

AIM2

To probe mechanisms underlying differentiation-dependent changes in
mRNA levels of glucose transporters and other highly regulated genes.
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Experimental Design
1- Assess whether changes of mRNA levels are due to changes in the
transcription rate.
2- If changes in mRNA abundance are not fully explained by changes in
transcription rate, I will examine the stability of mRNA for selected genes.

Project Significance
This study of adipocyte cell differentiation induced by a novel hypoglycemic
agent will deal with several important areas. First, it will provide useful insight
into the regulatory mechanisms involved in the adipocyte differentiation and
development, and information on the molecular basis for the development of
responsiveness to certain hormones such as insulin. Second, adipocytes are
known to play an important role both in normal physiology as a major site for
energy storage and release, and in certain pathological states such obesities and
obesity-linked diabetes. Therefore, studying the adipocyte gene expression is of
great interest because it might provide clues on how disordered gene expression
in such disease states would adversely affect the adipocyte function. In addition,
this study will expand our understanding of how the hypoglycemic agent
pioglitazone acts in vivo to enhance insulin sensitivity of target tissues thus
correcting elevated blood glucose levels in diabetes. Finally, this combined use
of cell culture and pioglitazone treatment should prove to be a useful model
system with which to study the molecular mechanisms underlying insulin action
on glucose transport.

CHAPTER III

MATERIALS AND MEIHODS

3T3-F442A cells (39) were kindly provided by Dr. J. Schwartz (University of
Michigan, Ann Arbor, MI) and pioglitazone was provided by the Upjohn Co.
(Kalamazoo, MI). All tissue culture media and reagents were obtained from
Sigma Co. (St. Louis, MO). Culture plates were purchased from Coming glass
works (Coming, NY). Guanidine isothiocynate and formamide were purchased
from International Biotechnologies, Inc. (New Haven, CT). Nytran nylon
membranes were purchased from Schleicher and Schuell (Keene,NH), and
Riboprobe preparation kits were obtained from Promega Corp. (Madison, WI).
Cytidine 5' -[a-32p] triphosphate ( > 800Ci/ mmol), U ridine 5' -[ a-32P]
triphosphate (800Ci/mmol), and D-[U- 14C] Glucose (>230 mCi/mmol) were
purchased from Amersham Corp. (Arlington Heights, IL). Immobilon PVDF
membranes were obtained from Millipore Corp. (Bedford, MA). Immunoblot
assay kit and the alkaline phosphatase-conjugated secondary antibody (GARAP) were purchased from Bio-Rad (Richmond, CA). Nonident P40 was
purchased from Boehringer Mannheim (W. Germany). All other chemicals
were obtained from Sigma Chemical Co. (St.Louis, MO).

Cell Culture and Differentiation
Cells were routinely grown in Dulbecco's Modified Eagle's medium
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(DMEM; 4.5 g/liter glucose) in the presence of 10% (vol/vol) calf serum. All
formulations of DMEM contained glutamine (2 mM), penicillin (50 U/ml),
streptomycin (50 µg/ml), and fungizone (0.25 µg/ml). The cells were
inoculated onto 100-mm culture dishes at a density of 500/ cm2, or 35-mm 6well plates at a density of 1500/ cm2, then were grown to confluence and
maintained at 37°C in a humidified 10% C02190% air atmosphere. Medium
was changed every 2-3 days. To induce differentiation to adipocytes, confluent
fibroblast cultures were switched to differentiation medium, DMEM containing
10% (vol/vol) fetal calf serum and supplemented with insulin (1 µg/ml),
pioglitazone (1 µM) unless otherwise indicated. Cell differentiation was
assessed judging cell morphology under phase contrast microscopy; cells were
considered to be adipocytes if numerous lipid droplets were observed in the
cytoplasm. The cell line was used during 10th to 20th passage after clone
isolation. To maintain a stock of 3T3-F442A fibroblasts at an early passage,
cells were frozen in 15% (vol/vol) Dimethyl Sulfoxide (DMSO)/ culture
medium and stored in liquid nitrogen.

Measuzement d Tn"glyceride Accumulation
Triglyceride accumulation was measured by an organic extraction method
adapted from J. Schwartz (146). Briefly, monolayers of 3T3-F442A cells on 100mm dishes were washed once with sterile phosphate buffered saline (PBS, 2.68
mM KCl, 8.1 mM Na2HP04, 1.5 mM KH2P04, 136.9 mM NaCl) and released
from the plate with 3 ml of 0.05% trypsin-EDTA (Gibco Co., Grand Island,
NY) in sterile PBS. An aliquot of cells was delivered to a hemocytometer for
cell counting and another measured aliquot (0.3 ml) was delivered into 5 ml
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Dole's reagent (isopropyl alcohol: heptane: 1NH2S04;40: 10: 1), then 3 ml
heptane and 2 ml water were added to convert into a 2-phase system. After
vigorous mixing, the phases were allowed to separate and the volume of the
upper heptane phase was measured. A volume of the upper heptane phase (3
ml) was delivered into a tared glass scintillation vial, dried, and the vial was

weighed. The difference in weight indicates triglyceride amount.

Cell counting
Cell monolayers were washed with PBS and released from plate with 3 ml ( 1
ml for 35-mm plates) 0.05% trypsin-EDTA. A drop of cell suspension was

placed in the upper and lower chambers of a hemocytometer, and cells in a total
of 10 (1mm2x0.1 mm) squares were counted. This gives the number of cells in
O.lmm3.
Cell/ cm3

= cells counted x 10,000/ 10 (number of squares counted).

Calculation of triglyceride accumulation per cell
mg triglyceride per ml cell suspension:

[mg triglyceride x total vol. heptane phase/3.0 (ml heptane used)] x [1/0.3 (ml
of cell suspension used)]

This number divided by the number of cells in a ml yields mg triglyceride per
cell.
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Measwement d 2-deoxy [14CJ Glucose Uptake

Cell monolayers on 35-mm, 6-well plates (Corning brand) were rinsed once
with PBS, and incubated in assay medium [DMEM, no-glucose, 5 mM sodium
bicarbonate, 25 mM N-2-hydroxyethylpiperazine-N' -2-ethanesulfonic acid
(HEPES), pH 7.4, 0.1% bovine serum albumin BSA; BIOLOGOS INC.
Naperville, IL] 15 min at 22°c. 0.5 µCi of D-(u- 14c] glucose in assay medium
was added to each well and further incubated 15 min at 22°c. The cells were
rinsed three times with PBS + 10 mM glucose, and solubilized by incubation
with 0.9 ml of 0.5 N NaOH 30-40 min at 37°C, and transferred to vials. The
mixture was neutralized by addition of 105 µl glacial acetic acid, and
radioactivity was counted using 10 ml Beckman Ready-Solv CP (147).

Cell countin~ and calculations
Cells corresponding to each treatment condition were released from 35-mm,
6-well plates with 1 ml of 0.05% trypsin-EDTA and were counted using
hemocytometer as described under triglyceride accumulation. Cell-associated
radioactivity measured by scintillation counting as Disintegrations per minute
(DPM) was divided by the number of cells for each treatment condition to yield
DPM per cell.

N01them Blot Analysis d RNA

Total RN A was extracted from cell monolayers by the guanidinium
isothiocyanate extraction method adapted from Chomczynski and Sacchi (148).
Briefly, cell monolayers were rinsed with sterile PBS and scraped into guanidine
thiocyanate solution (4 M guanidine thiocyanate, 25 mM sodium citrate, 0.5%
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Sarkosyl and 0.1 M 2-mercaptoethanol; GTS), and extracted with
phenol/ chloroform in the presence of high salt concentration. The two layers
were separated by centrifugation at 7,800 xgand RNA in the aqueous layer was
precipitated with an equal volume of isopropanol at -70°C. RNA was further
resuspended in GTS and reprecipitated, and the final RNA pellet was
resuspended in DEPC (Diethyl pyrocarbonate)-treated H20 and stored at -

10°c. RNA yield was calculated using an O.D. 260 reading in
spectrophotometer and assuming each 1 O.D. unit

= 40 µg/ml RNA.

Electrophoretic size-fractionation of RN A ( 10 µg/lane) through 1% agarose
gels and transfer to nylon membranes were performed according to the
technique of Fourney et al (149). RNA was cross-linked to the membrane using
a UV Stratalinker (Stratagene, La Jolla, CA) and hybridized to antisense RNA
Riboprobes prepared according to kit protocols (Promega Corp.).
High stringency hybridizations were performed at 65°C in a solution of 10%
dextran sulfate, 50% formamide, 5 x SSPE (1 x SSPE = 180 mM NaCl, 10 mM
NaP04, and 1 mM EDTA, pH 7.4), 5 x Denhardt's solution (100 x

= 2% Ficoll,

2% BSA, and 2% polyvinylpyrrolidone ), 0.1 % sodium dodecyl sulfate (SDS),
and denatured sheared salmon sperm DNA (100 µg/ml). Dextran sulfate was
omitted in some cases from hybridization solution to reduce background. The
membranes were washed at 70°C twice in 2 x SSC (1 x

= 150 mM NaCl and 15

mM sodium citrate, pH 7.0) with 0.1 % SDS and twice in 0.1 x SSC with 0.1 %
SDS. Membranes were exposed to Kodak XAR-5 film (Eastman Kodak,
Rochester, NY) or to Amersham Hyperfilm-MP (manufactured for Amersham
by CEA AB, Sweden) at -70°C with an intensifying screen (2-16 hr).
Autoradiographic bands were quantitated by two dimensional densitometry on

34
a Bio-Rad 620 Scanner (Richmond, CA) or on an AMBIS image acquisition
analysis system (San Diego, CA). Hybridizations were performed under
conditions where autoradiographic detection was in the linear response range.
To correct for unequal RNA loading, Northern blots were photographed with
Polaroid type55 positive/ negative black and white film, and the fluoresence of
the ethedium bromide-intercaleted 28S rRNA band on negative films was
quantitated by two dimensional densitometry. The system was validated by
demonstrating that the signal was linear at least over the range of 1-12.5 µ.g
RNA/lane (150,151).

Description of plasmids
Riboprobes for GLUTl were prepared using the entire coding region of rat
brain glucose transporter from pSPGT-1 (152) obtained from Dr. Graeme Bell
(Chicago, IL). The insert was excised using Bgl II and subcloned into the Barn
HI site of pGEM-4Z. The construct was linearized with Eco RI, and TI RNA
polymerase was used for preparation of Riboprobes.
Riboprobes for GLUT4 were similarly prepared using pSM 1D2 obtained
from Dr. Morris Birnbaum (Boston, MA). The construct contains a 1.5-kilobase
(kb) 5' fragment of cDNA encoding the rat GLUT4 protein (153). This
construct was linearized with EcoRI, and TI RNA polymerase was used for
transcription.
Riboprobes for adipsin were prepared using pGEM-4Z containing a mouse940bp insert (pAD-20) from Pst I site of pBR322 (85) obtained from Dr. Bruce
Spiegelman (Boston, MA) and subcloned in our laboratory. The construct was
linearized with Eco RI and TI RNA polymerase was use for transcription.
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Similarly, Riboprobes for aP2 were prepared using a mouse-390bp insert
called pAd-5 (85) obtained from Dr. Bruce Spiegelman and subcloned in our
laboratory from pBR322 into the Pst I site of pGEM-4Z. The construct was
linearized with Hind III, and SP6 RNA polymerase was used for preparation of
Riboprobes.
For the insulin receptor (IR), a 775bp insert for the mouse insulin receptor
(original clone provided by Dr. G. Bell and has not been formally described in
the literature) was subcloned in our laboratory from pUC into the EcoRI site of
pGEM-3Z. It was linearized with Hind III, and 17 RNA polymerase was used
for preparation of Riboprobes.

Plasmid DNA preparation
Plasmid DNA was prepared using Qiagen plasmid preparation kit (Qiagen
Inc. Chatworth, CA). Cultures were inoculated from frozen (-70°C) stocks of

Ecoliusing 10 µl per 50 ml of 2.5% LB Broth culture medium, and incubated
overnight in an environmental shaker at 200-250 rpm. Cells were harvested by
centrifugation when the O.D.600 reached 1-1.5, and plasmids were isolated
following the kit protocol. This procedure yielded 100 µg (midi-prep kit) to 500
µg (maxi-prep kit) DNA.

Western Immunoblot Analysis

Total particulate membrane proteins were prepared as previously described
(61). Briefly, cells were washed with PBS and scraped into homogenization
buffer (20 mM Tris, 255 mM Sucrose, 1 mm ethylenediaminetetraacetic acid
EDTA, 1 mm phenylmethyl sulfonyl fluoride PMSF, 10 units/ml Trasylol) and
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were homogenized with ten strokes of Tekmar tissumizer (Tekmar Inc,
Cincinnati, OH). Total membranes were prepared by centrifugation of the
homogenate at 200,000 xg4°C 75 min. Protein concentrations were determined
by the Bradford assay (154) using Bio-Rad/Bradford Protein Assay Kit and
bovine serum albumin as a standard. Initial Western blot experiments revealed
diffuse bands of GLUTl and GLUT4 proteins, possibly due to heterogeneous
glycosylation of the transporter proteins. Therefore, protein samples were
routinely treated with peptide N-glycosidase F (1 unit per 100 µg protein;
Boehringer Mannheim) in a buffer containing 20 mM sodium phosphate, pH
7.5, 10 mM EDTA, 1.7% Triton x-100, 1 mm PMSF for 48-72 hr at 37°c (109)
to remove sugar residues, and then mixed with 1/ 4 vol of 4 x electrophoretic
sample buffer (200 mM Tris-HCl, pH 6.8, 400 mM dithiothreitol, 8% SDS, 40%
glycerol, 0.4% bromophenol blue) and stored at -20°C. Samples were thawed
and loaded in parallel onto two discontinuous 12% polyacrylamide gels, and
size-fractionated using a Mini Protean II Dual Slab Cell (Bio-Rad) according to
the method of Laemmeli (155). The amount of protein loaded (10 µg/lane for
GLUTl and 60 µg/lane for GLUT4) was empirically determined to be within
the linear response range of the detection system used. Separated proteins
from both gels were electrophoretically transferred to Immobilon PVDF
membranes (Millipore Corp., Bedford MA) using a Mini Trans-Blot
Electrophoretic Transfer Cell (Bio-Rad). One membrane was stained with
Coomassie R-250 (0.1% Coomassie R-250, 40% methanol, 10% acetic acid) for
total protein. The second membrane was used for the colorimetric detection of
GLUTl or GLUT4 using a double antibody system and the Immuno-Blot Assay
Kit (Bio-Rad). Manufacturer's instruction were followed, except 5% BSA was
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used for membrane blocking. The primary antibody (RaIRGT, against GLUT4
and RaGLUTRANS against GLUTl, East Acres Biologicals, Southbridge, MA)
were diluted to 1:2000 and 1:3000 respectively and the alkaline phosphataseconjugated second antibody (GAR-AP, Bio-Rad) was diluted 1:3000 before use.
Resulting signals were quantitated with the reflective mode of a model 620
Video Densitometer (Bio-Rad). Sample loading corrections were made based
on densitometry data from the Coomassie-stained membrane.

Run-on Transcription Activity
Nuclei were isolated from 3T3-F442A cells by a method adapted from
Konieczny et al (156). Cell monolayers were washed twice with resuspension
buffer RSB (10 mM Tris, pH 7.5, 10 mM NaCl, 3 mM MgCl2); scraped from
plates in RSB + buffer (10 mM Tris, pH 7.5, 10 mM NaCl, 3 mM MgCl2, 0.5%
N onident P40, 2.75 mM DTT), and disrupted by 10 strokes in a Dounce glass
homogenizer. The nuclei were concentrated by centrifugation at 1000 x g and
suspended in nuclei suspension buffer NSB (50 mM HEPES, pH 8.0, 5 mM
MgCl2, 0.1 mM EDTA, pH 8.0, 2 mM DTT, 40% glycerol) stored at -70°C.
Nuclear transcription assays were adapted from Sasaki et al (157) with some
modifications. Briefly, after thawing on ice, equal amounts of nuclei (0.5-1 mg
DNA) - assessed by fluorometric quantitation of DNA (158)- were used in
assays carried out at 26°C for 20 min in a solution of 75 mM Hepes, pH 8.0, 100
mM KCl, 0.1 mM EDTA, 0.1 mM PMSF, 0.5 mM CTP, 0.5 mM ATP, 0.5 mM
GTP, 0.25 U/ml RNasin, 1 µCi/ µl aP32_UTP -800 Ci/mM) in a total reaction
vol of 140 µl. The assays were terminated by incubation with 2 x stopping buffer
(40 mM Tris, pH 7.5, 20 mM CaCl2, 200 µg/ml proteinase K, 250 µg/ml tRNA,
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5 U/ml RNase-free DNase) for 20 min at 37°C. Nuclei were digested with
EDTA/SDS (100 mM EDTA, pH 8.0, 8% SDS) for 10 min at 37°C and RNA
was isolated by chloroform/phenol extraction (1:1), and precipitation with 7.5
M ammonium acetate-100% ethanol. RNA transcripts were resuspended in 1 x
stopping buffer (without tRNA) and incubated for 20 min at 37°C, followed by
another EDTA/SDS digestion, phenol/ chloroform extraction and precipitation
as above. The transcripts were suspended in T.IE suspension buffer (0.1 mM
EDTA, pH 8.0, 10 mM Tris, pH 7.5) and reprecipitated. RNA transcripts were
resuspended in 200 µl hybridization solution (50% formamide, 5 x SSPE, 5 x
Denhardt's solution, 0.1 % SDS, 200 µgl ml denatured sheared salmon sperm
DNA solution), the amount of RNA-associated 32P-radioactivity determined by
liquid scintillation counting. Samples were adjusted to contain equal amounts
of radioactivity using hybridization solution (1-2 x 107 cpm). Hybridizations
were carried out in a total volume of 500 µ.l at 65°C for 18-24 hr using nylon
membranes to which 1 µ.g of each cRNA was applied using a dot-blot apparatus
(Mini-fold, Schleicher and Schuell, Keene, NH) and attached by UV crosslinking. 1 µg was empirically found to be appropriate for signal detection. Each
cRNA was prepared from its vector plasmid as described for Northern Blotting
using RNA Riboprobe Kit according to kit protocol (Promega Corp.), and
confirmation of full length transcripts was made by electrophoresis with
molecular markers on 1% agarose gel. cRNA Riboprobes for the plasmid
vector control (pGEM-4Z) and appropriate genes were denatured in a solution
containing 50% formamide, 16.2% formaldehyde for 15 min at 65°C and
applied to the membrane in 10 x SSC buffer. Membranes were first
prehybridized for 2 hr at 65°C in hybridization solution. After hybridization,
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filters were washed at 70°c twice in 2 x SSC with 0.1 % SOS and twice with 0.1 x
SSC with 0.1 % SOS. Membranes were then exposed to Kodak XAR-5 films at -

10°c for 2-4 days. Filters were then cut and 32P-labeled radioactivity
hybridized to each cRNA Riboprobe was released from filters with 0.04 N
NaOH and neutralized with 0.1 N acetic acid. Five ml of Beckman Ready-Solv
CP scintillation fluid were added and radioactivity was quantitated by
scintillation counting.

DNA quantitation by fluorescence
To determine the amount of nuclei needed for each transcription reaction,
the amount of DNA was measured according to the method of Labarca and
Paigen (158). Briefly, an aliquot of nuclei was delivered into phosphatebuffered saline with EDTA (PBSE

= 0.05 M Na2HP04, 2 M NaCl, 2 mM

EDTA, pH 7.4) and sonicated for 10 seconds. The compound Hoechst 33258,
(2-[2-(4-hydroxy phenyl)-6-benzimidazolyl]-6-( 1-methyl-piperazyl)benzimidazol.3H Cl) (Sigma Co. St.Louis, MO), was added to each sample and
the fluorescence enhancement was measured in fluorometer with excitation set
at 356 nm and emission set at 458 nm. Calf thymus DNA was used to generate
a standard curve.

Measwement d mRNA Stability
Confluent monolayers of 3T3-F442A cells were differentiated with insulin,
pioglitazone or both agents as described under cell culture and differentiation.
On day 7 of differentiation, mRNA synthesis was inhibited by addition to the
medium of actinomycin D-mannitol (Sigma Co. St.Louis, MO) to a final
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concentration of 5 µglml. Total RNA was extracted from separate monolayer
cultures at 0, 1, 2, 4, 6, and 24 hr after the addition of transcription inhibitor.
Messenger RNA transcript abundance was determined by Northern blot
analysis and hybridization and densitometry of resultant autoradiographic bands
as described above.

Calculations
Data were expressed as percent of mRNA remaining after actinomycin D
treatment relative to their levels before the treatment (time 0). The half life of
each message was calculated using the Enzfitter program (Elsevier Biosoft,
Elsevier Science Publishers, Amesterdam). mRNA levels were fitted to a
single exponential decay curve according to the equation y

= Exp (-k.t) by non

linear least square regression analysis. In this equation, y, is the concentration
at time 't', and k is the first order rate constant of the exponential decay plot.
The half-life of mRNA was then calculated by dividing ln2 with k.

Statistical Analysis
Statistical analysis was performed using SAS version 6 (SAS institute, Inc.,
Cary, NC). All hypothesis tests were two-sided and were considered significant
if p-value was less than or equal to .05
Dose-response experiments were analyzed using one-factor analysis of
variance (ANOVA). In one set of analyses, the factor was dose of insulin, and
in the second set of analyses, the factor was dose of pioglitazone. If there was a
significant dose response, then Tukey's pairwise comparison procedure was
used to locate the differences among dose levels.
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Time-course experiments were analyzed using a three-factor analysis of
variance (ANOVA) with interactions procedure. The factors used were day of
the experiment, insulin or control, pioglitazone or control. Beginning with the
higher order interaction terms, successive models were run deleting one nonsignificant factor or interaction at a time until the final model only contained
terms which were significant at p ..::;.0.05.
Protein experiments and time-course experiments, in some cases, were
analyzed using a two-factor analysis of variance with interaction procedure.

CHAPTER IV
RESULTS

Hfects d insulin and pioglitawne on 3T3-F442A preadipocyte differentiation
Treatment of confluent 3T3-F442A cells with insulin (1 µg/ml), pioglitazone
(1 µM), or both agents in the presence of 10% fetal calf serum resulted in
conversion of cells into lipid-accumulating adipocytes as assessed by phase
contrast microscopy (Table I, Figure 1). While only limited numbers of cells
differentiated into adipocytes by either treatment alone, both agents had
approximately additive effects shown most clearly on day 3 (I, 8 .± 3; P, 15 .± O;

I+ P, 30 + 5) and day 5 (I, 42 .± 8; P, 45 .± 4; I+ P, 84 .± 5) and reaching
maximal levels on day 7 (I+ P, 95 .± 0) of differentiation. These morphological
changes were accompanied by time-dependent changes in cellular triglyceride
content (Figure 2), assessed by organic extraction of triglyceride. This effect
was measurable on days 3, 5, and 7. There were marked changes on day 7 of
differentiation (C, 0.39 .± 0.05; I, 0.599 .± 0.07; P, 1.34 .± 0.19; I+ P, 2.2 .± 0.27).
These results indicate that both insulin and pioglitazone act as accelerators of
adipocyte differentiation and that their effects are additive or synergistic.

Hfects d insulin and pioglitawne on glucose transpoit activity and glucose
transpoiter ~ne expression
To determine whether the observed cell differentiation was accompanied
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Table I. Pioglitazone and insulin-dependent differentiation of 3T3-F442A
expressed as% differentiated cells.

Day

cs

INS

PIO

INS+PIO

0
1
3
5

0
0
2
2
2

2
8
42
60

2
15
45
80

3
30
84
95

7

Cells were plated, grown to confluence and maintained in Dulbecco's
modified Eagle's medium (DMEM) supplemented with 10% calf serum. To
induce differentiation, cells were switched to DMEM medium supplemented
with 10% fetal calf serum, insulin (INS), pioglitazone (PIO) or both (I+ P) as
described under materials and methods. Untreated age-matched fibroblasts
maintained in growth medium with only calf serum (CS) were used as control.
Cell differentiation was assessed by phase contrast microscopy. Data represent
mean values for n

= 2-6 determinations.

One-way analysis of variance

(ANOVA) on day 7 for CS vs INS, CS vs PIO, CS vs INS+ PIO, p < 0.0001.
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B. Adipocytes

Figure 1. Phase contrast microscopy showing the change in morphology upon

differentiation from preadipocytes (A) to adipocytes (B) induced by treatment
with a combination of insulin and pioglitazone. Magnification x300.
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Figure 2. Time-course showing increasing abundance of triglyceride during
differentiation of 3T3-F442A fibroblasts into adipocytes. 3T3-F442A cells were
plated, grown to confluence and differentiated with INS (1 µg/ml), PIO (1 µM),
or both (INS+ PIO) as described under materials and methods. At indicated
time points, triglycerides were extracted from cells with Dole's reagent and the
organic layer was dried. Triglyceride accumulation was determined by weighing
the dried residue. Untreated age-matched fibroblasts maintained in growth
medium (CS) were used as control.
Each data point represents mean ± S.E.M for n

= 9 determinations.

A three

factor analysis of variance (ANOVA; insulin, pioglitazone, time) with
interactions showed significant time-dependent effects on triglyceride
abundance by INS (p

= 0.017), PIO (p

<0.0001), INS+ PIO (p

= 0.02).
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with changes in cellular metabolic activities, we examined the transport level of
2-deoxy [14c] glucose into cells differentiated with insulin and/ or pioglitazone
as compared to control undifferentiated cells. Differentiation of 3T3-F442A
cells with insulin, pioglitazone, or both agents, resulted in enhanced basal 2deoxy glucose transport in a time-dependent manner (Figure 3). While either
insulin or pioglitazone alone showed respectively 22- and 29-fold enhancement
above control of glucose transport on day 7 of differentiation, both agents acted
synergistically to increase glucose transport activity on each of the days
examined, reaching maximal levels of 96-fold on day 5 and seemingly started to
decline to lower levels (46-fold) on day 7 of differentiation. Age-matched
undifferentiated cells kept in growth medium showed no increase glucose
transport during the same period of time, and even showed a 40% decline in
their rate of glucose transport by day 7, possibly an indication of the cells
becoming more quiescent.
To assess whether such enhanced glucose transport activity could be
explained by changes in adipocyte-glucose transporter expression, we analyzed
the levels of GLUTl and GLUT4 mRNA and protein abundance. GLUTl
mRNA abundance increased in a dose-dependent manner reaching maximal
levels of 2.5-fold and 2-fold after 7 days of treatment with 10 µgl ml insulin
(Figure 4A) and 10 µM pioglitazone (Figure SA), respectively, as compared to
undifferentiated control cells (day 0). Age-matched undifferentiated cells kept
in growth medium showed < 10% increase in GLUTl mRNA abundance at the
same time. In contrast to this moderate elevation of GLUTl mRNA, GLUT4
mRNA abundance was dramatically increased in a dose-dependent manner as
much as 20-fold above its levels in undifferentiated cells by either insulin
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(Figure 4B) or pioglitazone (Figure SB). Age-matched cells kept in growth
medium showed <2.5-fold increase in GLUT4 mRNA abundance.
Furthermore, GLUT4 mRNA abundance was significantly increased by the
lowest tested dose of each of insulin and pioglitazone, with maximal effects at S
µglml insulin (Figure 4B) and 1 µM pioglitazone (Figure SB).

In addition, both mRNA transcripts analyzed by Northern blotting, increased
in a time-dependent manner during differentiation. While either insulin (1
µg/ml) or pioglitazone (1 µM) treatment increased GLUTl mRNA abundance
by 2.3- and 1.S-fold, respectively, above undifferentiated cells (day 0), insulin
and pioglitazone together acted synergistically to increase this message by
almost 6-fold by day 7 (Figure 6). GLUTl mRNA levels did not change during
the same period in undifferentiated age-matched cells kept in growth medium.
In contrast to the observed synergism on GLUTl mRNA, GLUT4 mRNA
abundance increased to similar levels above undifferentiated cells (day 0), 3.8-,
4.6, and S.2-fold by insulin, pioglitazone, or both, respectively (Figure 7).
These changes in GLUTl and GLUT4 mRNA levels were accompanied by
changes in their respective protein products as assessed by Western blotting.
While either insulin or pioglitazone treatment increased GLUTl protein levels
on day 7 of differentiation by 2.3-and 3.5-fold, respectively, both agents acted
synergistically to increase GLUTl protein levels by almost 10-fold (Figure 8)
above those in their age-matched undifferentiated cells. In contrast to the
observed synergistic effect on GLUTl protein, GLUT4 protein levels increased
by 2.2-, 6.6-, and 4-fold by insulin, pioglitazone, or both, respectively (Figure 9).
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Figure 3. Time-course showing increasing glucose transport activity during
differentiation. Confluent 3T3-F442A cells on 35 mm, 6-well plates were
induced to differentiate into adipocytes by insulin (INS), pioglitazone (PIO) or
both (INS+ PIO). On indicated time points, glucose transport activity was
determined by measuring cell-associated radioactivity following the uptake of 2deoxy-D-[U-14c] Glucose as described under materials and methods.
Untreated, age-matched fibroblasts maintained in calf serum growing medium
(CS) were used as control. Each data point represents mean.± S.E.M for n
determinations. A two way analysis of covariance (ANCOVA) showed
significant effects on glucose uptake by INS (p
INS+ PIO (p <0.0001).

= 0.0006), PIO (p

< 0.0001 ),

=3
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Figure 4. Insulin dose effect on GLUTl and GLUT4 mRNA abundance. 3T3F 442A cells were plated and grown in DMEM containing 10% calf serum. To
induce differentiation, confluent fibroblasts were maintained in DMEM
containing 10% fetal calf serum and supplemented with insulin at 0, 0.1, 1, 5, 10

µglml. Total RNA was isolated from cells on day 7. Samples of total RNA (10
µgllane) were electrophoretically size-fractionated on agarose gels, and
Northern blots were hybridized to Riboprobes specific for the rat GLUTl
mRNA (A), or the rat GLUT4 mRNA (B). Autoradiographic bands were
quantitated by densitometry and normalized for loading based on the
abundance of the 28S ribosomal RNA. Each data point represents mean±
S.E.M for n

= 6 determinations.

One way ANOVA showed significant dose-

dependent effect of insulin treatment on mRNA abundance for GLUTl (p
<0.0001) and GLUT4 (p

= 0.006).
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Figure 5. Pioglitazone dose effect on GLUTl and GLUT4 mRNA abundance.
3T3-F442A cells were plated and grown to confluence as described under
materials and methods. Differentiation was induced by maintaining cells in
DMEM containing 10% fetal calf serum and supplemented with 0, 0.1, 1, 5, 10

µM pioglitazone. Total RNA was isolated from cells on day 7, and samples of
10 µg/lane were electrophoretically size-fractionated on agarose gels. Northern
blots were hybridized to Riboprobes specific for the rat GLUTl mRNA (A), or
the rat GLUT4 mRNA (B). Autoradiographic bands were quantitated by
densitometry and normalized for correct loading base on the 28S ribosomal
RNA abundance. Each data point represents mean ± S.E.M for n

=6

determinations. One way ANOVA demonstrated significant dose-dependent
effect of pioglitazone on mRNA abundance for GLUTl (p <0.0001) and
GLUT4 (p

= 0.0001)
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Figure 6. Effect of insulin and pioglitazone treatments on GLUTl mRNA
abundance. A, Time-course showing increasing abundance of GLUTl mRNA
during differentiation of 3T3-F442A cells. Cells were plated, grown to
confluence and differentiated with insulin (INS), pioglitazone (PIO), or both
(INS+PIO) as described above. Total RNA was isolated on indicated time
points (days 1, 3, 5, 7). 10 µg of total RNA were electrophoretically sizefractionated on agarose gels and Northern blots were hybridized to Riboprobes
specific for rat GLUTl mRNA. Autoradiographic bands were quantitated by
densitometry and normalized for loading based on 28S ribosomal RNA
abundance. Untreated age-matched fibroblasts maintained in growth medium
(CS) were used as control.
Data represent mean values for n

= 5-6 determinations.

A three factor analysis

of variance (insulin, pioglitazone, time) with interactions showed significant
effect on GLUTl mRNA abundance from combined treatment with insulin and
pioglitazone (p

= 0.0001).

B, Representative blot showing GLUTl mRNA

abundance in control CS cells and in cells treated with INS, PIO, INS+ PIO on
day 7 of differentiation.
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Figure 7. Effect of insulin and pioglitazone treatments on GLUT4 mRNA
abundance. A, Time-course showing increasing abundance of GLUT4 mRNA
during differentiation of 3T3-F442A cell. Cells were plated, grown to
confluence, and differentiated by insulin (INS), pioglitazone (PIO) or both
(INS+ PIO) as described above. On indicated time points, total RNA was
isolated and 10 µg of it were electrophoretically size-fractionated on agarose
gels. Northern blots were hybridized to Riboprobes specific for rat GLUT4
mRNA. Autoradiographic bands were quantitated by densitometry and
normalized for loading based on the 28S ribosomal RNA abundance.
Untreated age-matched fibroblasts maintained in growth medium (CS) were
used as control. Each data point represents mean values for n

= 5-6

determinations. A three factor analysis of variance (insulin, pioglitazone, time)
with interactions showed significant effects on GLUT4 mRNA abundance by
INS (p

= 0.0001) or PIO (p

<0.0001). B, Representative blot showing GLUT4

mRNA abundance in control (CS) and treated (INS, PIO, INS+ PIO) cells on
day 7 of differentiation.
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Figure 8. Effect of insulin and pioglitazone treatments on GLUTl protein
abundance. Confluent 3T3-F442A cells were differentiated with 1 µ.g/ml
insulin (INS), 1 µ.M pioglitazone (PIO), or both (INS+ PIO), as described
above. On day 7, membranes were isolated from undifferentiated (CS) or
differentiated (INS, PIO, INS+ PIO- treated) cells, and 10 µ.g of protein were
electrophoresed and immunoblotted for GLUTl detection using the rabbit anti-

GLUTl primary antibody as described under materials and methods. Resulting
colorimetrically-stained bands were quantitated with densitometry and
normalized for loading based on desitometry data from Coomassie-stained
membranes. Data are expressed as% of control and represent mean± S.E.M
for n

= 8 determinations. Two factor analysis of variance showed significant

effects on GLUTl protein by INS (p

= 0.014), PIO (p = 0.015), and INS+ PIO

(p <0.0001). In control cells (CS), a non-specific band of an apparent
molecular weight of 60,000 (shown at arrow) cross reacted with secondary
antibody. Molecular weight markers are indicated in lane M.
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Figure 9. Effect of insulin and pioglitazone treatments on GLUT4 protein
abundance. Cell culture, treatment conditions, protein extraction, and Western
blot analysis were performed as described in the legend for Figure 8, except that
60 µ.g of total protein were loaded for GLUT4 detection using the rabbit antiGLUT4 primary antibody. Data are expressed as% of control and represent
mean.± S.E.M. for n

= 10 determinations. Two factor analysis of variance

showed significant effects on GLUT4 by INS (p
INS+ PIO (p

= 0.015), PIO (p = 0.007),

= 0.0003). In control cells (CS), a non-specific band of an

apparent molecular weight of 60,000 (shown at arrow) cross reacted with
secondary antibody. Molecular weight markers are indicated in lane M.
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Taken together, these results indicate that differentiation of 3T3-F442A cells
with insulin and pioglitazone is accompanied by concomitant increases in
glucose transport activity and glucose transporter gene expression on mRNA
and protein levels.

Hfects d insulin and pioglitamne on expression d adipocyte-spedfic genes
To determine whether the observed effect on glucose transporters is a
transporter-specific or a rather general effect on differentiation-dependent gene
expression, we examined the effect of insulin and pioglitazone during
differentiation on the expression of other known adipocyte-specific genes on
mRNA level. Differentiation of 3T3-F442A cells with either insulin (1 µg/ml)
or pioglitazone (1 µM) each increased adipsin mRNA levels in a timedependent manner, to as much as 5- and 11-fold on day 7 of differentiation, as
compared to undifferentiated control cells (day 0), (Figure 10). Age matched
undifferentiated cells kept in growth medium showed <2.5-fold increase in this
message during the same period of time. The combined insulin/ pioglitazone
treatment significantly inhibited expression of adipsin mRNA induced by either
treatment alone. On the other hand, aP2 mRNA abundance assessed under the
same conditions increased dramatically in a time-dependent manner by either
insulin, pioglitazone, or the combined treatment. These effects were seen as
early as day 1 of differentiation and reached maximal levels of 93- and 77-fold
on day 3 of differentiation by pioglitazone or insulin/pioglitazone respectively,
and after that the message levels start to decline (Figure 11). In contrast, aP2
mRNA abundance continues to increase with insulin treatment, though to much
lesser levels, reaching only 27-fold on day 7 of differentiation. Undifferentiated
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age-matched control cells kept in growth medium showed <3-fold increase in
aP2 mRNA abundance during the same period. In contrast to these high levels
of regulation on the abundance of both adipsin and aP2 mRNAs, no effect was
observed for any of the treatments on the abundance of insulin receptor mRNA
under same conditions even by day 7 of differentiation (Figure 12).
Since it is known that insulin has down-regulating effect on adipsin mRNA in
differentiated adipocyte cells (100), and it is also known that prolonged insulin
treatment down-regulates the insulin receptor itself in many tissues (58), we
decided to assess the abundance of these two messages after treatment and
withdrawal of the differentiation inducer in order to sort out differentiation
effects and down-regulation effects. For this experiment, 3T3-F442A cells were
differentiated with insulin (1 µg/ml), pioglitazone (1 µM), or both, in the
presence of 10% fetal calf serum, for 7 days, after which insulin and
pioglitazone were removed from the feeding medium and cells were kept in
medium containing only 10% fetal calf serum for another six days (day 13).
Total RNA was extracted from cells on day 7 and day 13, and the abundance of
adipsin and insulin receptor mRNAs was assessed on Northern blots.
Treatment of cells with either insulin or pioglitazone resulted in 5.6- and 6-fold
increase of adipsin mRNA while the combined treatment resulted in about 40%
decrease in the message on day 7 of differentiation when compared to
undifferentiated control cells - day 0 - (Figure 13). After insulin and
pioglitazone withdrawal, there is further increase in adipsin mRNA of about 6and 5.5-fold on day 13 above corresponding levels on day 7. Furthermore, such
withdrawal from cells differentiated with the combined insulin/ pioglitazone
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Figure 10. Effect of insulin and pioglitazone treatments on adipsin mRNA
abundance. A, Time-course showing increasing adipsin mRNA abundance
during differentiation 3T3-F442A cells induced by treatment with either insulin
(INS) or pioglitazone (PIO) alone and inhibitory effect by the combined
treatment (INS+ PIO). Cells were plated, grown to confluence and
differentiated with INS, PIO, or both (INS+ PIO) as described under materials
and methods. Total RNA was isolated on indicated time points, and 10 µg
samples were electrophoretically size-fractionated on agarose gels. Northern
blots were hybridized to Riboprobes specific for the mouse adipsin mRNA.
Autoradiographic bands were quantitated by densitometry and normalized for
loading based on the abundance of the 28S ribosomal RNA. Untreated agematched fibroblasts maintained in growth medium (CS) were used as control.
Each data point represents mean values for n

= 5-6 determinations.

A three

factor ANOVA (insulin, pioglitazone, time) with interactions showed significant
time-dependent effects on adipsin mRNA abundance by INS (p <0.0001) or
PIO (p <0.0001). The inhibitory effect of the combined treatment (I+ P) was
also significant (p <0.0001). B, Representative blot showing adipsin mRNA
abundance in control (CS) and treated (INS, PIO, INS+ PIO) cells on day 7 of
differentiation.
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Figure 11. Effect of insulin and pioglitazone treatments on aP2 mRNA
abundance. A, Time-course showing increasing abundance of aP2 mRNA
during differentiation of 3T3-F442A cells induced by INS, PIO, or INS+ PIO.
Cells were plated, grown to confluence, and differentiated as described in
materials and methods. Total RNA was isolated on indicated time points and
10 µ.g samples were electrophoretically size-fractionated on agarose gels.
Northern blots were hybridized to Riboprobes specific for the mouse aP2
mRNA. Autoradiographic bands were quantitated by densitometry and
normalized for loading based on the abundance of the 28S ribosomal RN A.
Untreated age-matched fibroblasts maintained in growth medium (CS) were
used as control. Each data point represents mean values for n

= 5-6

determinations. A two factor analysis of covariance (ANCOVA) showed
significant effects on aP2 mRNA abundance by INS (p
<0.0001), INS+ PIO (p

= 0.02), PIO (p

= 0.0002). B, Representative blot showing aP2 mRNA

abundance in control (CS) and treated (INS, PIO, INS+ PIO) cells on day 7 of
differentiation.
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Figure 12. Insulin and/ or pioglitazone treatments showed no significant effect
on insulin receptor mRNA abundance. 3T3-F442A cells were plated, grown to
confluence, and differentiated with INS, PIO, or INS+ PIO as described under
materials and methods. Untreated age-matched fibroblasts (CS) were used as
control. Total RNA was isolated on selected time points (day 1, 3, 5, 7) of
differentiation. Samples of 10 g of total RNA were electrophoretically sizefractionated on agarose gels and Northern blots were hybridized to Riboprobes ·
specific for the mouse insulin receptor mRNA. The blot represents typical
results on day 7 of differentiation.
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Figure 13. Enhanced adipsin mRNA abundance by insulin and pioglitazone
withdrawal after differentiation. 3T3-F442A cells were plated and
differentiated as described under materials and methods. On day 7 of
differentiation, insulin and pioglitazone were removed from differentiation
medium and cells were maintained in DMEM containing 10% fetal calf serum
for 6 days after which total RNA was isolated and the abundance of adipsin
mRNA was assessed using Northern blotting analysis as described earlier. A
quantitation of autoradiographic bands corresponding to adipsin mRNA
transcripts is shown. Each data point represents mean ± S.E.M for n

=4

determinations. Student's test for unpaired groups showed significant effects for
INS withdrawal (p = 0.007), PIO withdrawal (p = 0.002), and INS+ PIO
withdrawal (p

= 0.0002).
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Figure 14. Enhanced insulin receptor mRNA abundance by insulin and
pioglitazone withdrawal after differentiation. Cell culture, differentiation,
treatments, and message abundance analysis as described for figure 13. A,
Quantitation of autoradiographic bands corresponding to the 9.5 kb insulin
receptor mRNA transcript. Each data point represents mean± S.E.M for n

=

4 determinations. Student's test for unpaired groups showed significant effects
on the abundance of the 9.5 kb insulin receptor message by INS (p

= 0.0002),

PIO (p = 0.0007), and INS+ PIO withdrawal (p <0.0001). B, Quantitation of
autoradiographic bands corresponding to the 7.5 kb insulin receptor mRNA.
Each data point represents mean± S.E.M for n

= 4 determinations. Student's

test showed significant effects on the 7.5 kb insulin receptor message abundance
for INS withdrawal (p = 0.005), PIO withdrawal (p = 0.0016), and INS+ PIO
withdrawal (p < 0.0024 ). C, Representative blot showing enhanced expression
of insulin receptor message of two sizes after insulin and pioglitazone
withdrawal.
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treatment showed 29-fold increase of adipsin mRNA levels on day 13 above
their corresponding levels on day 7.
The insulin receptor 9.5 kb message increased about 2.6- to 3.4-fold on day
13 above corresponding levels on day 7 after insulin, pioglitazone, or
insulin/pioglitazone withdrawal (Figure 14A, 14C). Similar results were
obtained for the insulin receptor 7.5 kb message (Figure 14B, 14C).
Taken together, all these results indicate that both insulin and pioglitazone
have general differentiation effect, causing 3T3-F442A cells to differentiate into
adipocytes with concomitant increases in the expression of adipocyte specific
genes.

Hfect d insulin and pioglitaz.one on tmnscnption activity
To assess whether observed changes in abundance of different mRNAs were
due to changes in corresponding gene transcription rate, we performed the
nuclear transcription run-on assay. 3T3-F442A cells were differentiated with
insulin (1 µg/ml), pioglitazone (1 µM), or both, and nuclei were isolated from
differentiated cells on day 7 and from undifferentiated control cells on day 0.
Transcription activity was measured by allowing the incorporation of [3 2P]UTP
into elongating nascent transcripts in isolated nuclei, and hybridizing the
resultant labeled transcripts into immobilized cRNA Riboprobes of interest. As
shown in Figure 15 and in Table II, transcription activity was below detection
for GLUTl, GLUT4, and insulin receptor in control cells and no change could
be detected with differentiated cells. Unexpectedly high levels of transcription
activity were detected for adipsin and aP2 in undifferentiated control cells.
There are detectable increases in transcription activity for aP2 and detectable
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decreases for adipsin in differentiated cells. In all cases, changes in mRNA
abundance for all studied genes could not be explained by corresponding
changes in transcription activity.

Transcription Run-on Assay

NIM

llUT1

GLUT<

-...
crn•

Ill

cs

INS

PIO

l+P

Figure 15. Regulation of gene transcription activity by insulin and
pioglitazone-induced differentiation of 3T3-F442A cells. Nuclei were isolated
from cells differentiated with insulin (INS), pioglitazone (PIO), or both
(INS+ PIO) on day 7 of differentiation, and from preconfluent undifferentiated
cells (CS). Transcription run-on assay by isolated nuclei was carried out as
described under material and methods. Resultant labeled transcripts were
hybridized to indicated cRNAs (1 µg each), and to plasmid vector cRNA
(pGEM-4Z). A representative autoradiogram is presented from an experiment
performed twice each with a different preparation of nuclei.
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Table II. Regulation of gene transcription activity by insulin and pioglitazoneinduced differentiation of 3T3-F442A cells.

EXP. 1

GLUT1
GLUT4
INS.REC.
ADIPSIN
aP2

cs

INS

PIO

INS+PIO

N.D.
N.D.
N.D.
208
452

N.D.
N.D.
152
454

10
15
27
255
896

N.D.
N.D.
N.D.
142
595

cs

INS

PIO

INS+PIO

N.D.
N.D.
N.D.
181
395

N.D.
57
N.D.
125
524

0.6
N.D.
N.D.
131
569

N.D.
N.D.
N.D.
108
586

11

EXP.2

GLUT1
GLUT4
INS.REC.
ADIPSIN
aP2

Transcription run-on assay was carried out as described under figure 15.
After hybridization and autoradiography, filters were cut and 32 P-labeled
radioactivity hybridized to each cRNA was quantitated by scintillation counting.
Data are expressed as count per minute (cpm) after subtracting counts
corresponding to vector-associatd radioactivity as background. N.D. indicates
that signal was not detected.
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Hfect d insulin and pioglitazone on mRNA stability

Since observed increases in specific mRNA levels could not be explained by
corresponding increases in their transcription rates, we investigated possible
effects of insulin and pioglitazone on the stability of these mRNAs. 3T3-F442A
cells were differentiated with insulin (1 µg/ml), pioglitazone (1 µM), or both for
7 days. The transcription inhibitor agent, actinomycin D, was added at a final
concentration of 5 µg/ ml to differentiated cells on day 7 or to undifferentiated
control cells used just before reaching confluence (day 0), and total RNA was
extracted from cells at indicated times after addition of the transcription
inhibitor (0, 1, 2, 4, 6, 24 hr). The abundance of remaining mRNA transcripts
for each gene was assessed on Northern blots. Differentiation of 3T3-F442A
cells increased the GLUTl mRNA half life from about 2.2 hr in control
undifferentiated cells to about 6.3, 4.1, and 24 hr in cells differentiated with
insulin, pioglitazone, or both, respectively (Figure 16, Table III). The
magnitude of GLUTl mRNA stabilization likely accounts for the previously
described corresponding increases in GLUTl mRNA abundance. Similarly,
GLUT4 mRNA half life increased from about 1.2 hr in undifferentiated control
cells to about 20.2, 24, and > 24 hr in cells differentiated with insulin,
pioglitazone, or both, respectively (Figure 17, Table III). Again, the magnitude
of GLUT4 mRNA stabilization most likely accounts for described increases in
mRNA abundance. Adipsin mRNA half life also increased from about 5.9 hr in
control undifferentiated cells to more than 24 hr in cells differentiated with
either insulin or pioglitazone or both (Figure 18, Table III), and this increase in
half life could account for observed changes in mRNA abundance, except in the
case of the combined treatment were the observed decrease in mRNA steady
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state level could be due to transcriptional inhibition. On the other hand, there
was no measurable change in mRNA stability for aP2 which showed half lives of
more than 24 hr in control undifferentiated as well as differentiated cells
(Figure 19, Table III).
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Figure 16. Enhanced GLUTl mRNA stability by treatment with insulin,
pioglitazone, or both. Confluent 3T3-F442A cells were differentiated with INS,
PIO, or INS+ PIO for 7 days as described under materials and methods. On day
7, the transcription inhibitor agent actinomycin D (Act D) was added to
differentiated and undifferentiated (CS) control cells to a final concentration of
5 µg/ ml and total RNA was extracted from cells at indicated time points (0, 1,
2, 4, 6, 24 hr). Abundance of mRNA was assessed by Northern blotting analysis
as described earlier. A, Quantitation of autoradiographic bands corresponding
to the remaining GLUTl mRNA after Act D addition in undifferentiated and
differentiated cells. Data are expressed as percent of mRNA remaining after
Act D treatment relative to their levels before the treatment (time 0). Each
data point represents mean values for n

= 2 determinations. B, Blot showing

remaining GLUTl mRNA after transcription inhibition in an experiment done
in duplicate, except for the time "O" point of INS, where only a single sample is
shown. Hours of film exposure were 40, 18, 24, and 8 hr for CS, INS, PIO, I+ P
respectively.
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Figure 17. Enhanced GLUT4 mRNA stability by treatment with insulin,
pioglitazone, or both. Cell culture, differentiation, actinomycin D treatment,

and mRNA analysis were done as described under figure 16. Data, which
represent mean values for n

= 2 determinations, are expressed as percent of

mRNA remaining after Act D treatment relative to their levels at time 0.
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Figure 18. Enhanced adipsin mRNA stability by treatment with insulin,
pioglitazone, or both. Cell culture and differentiation, actinomycin D

treatment, and mRNA analysis as described under figure 16. Data, which
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Table III. Calculated mRNA half lives in hours for undifferentiated and
differentiated 3T3-F442Acells. Data from actinomycin D (Act D) treatment
experiment (Fig. 16, 17, 18, 19) were fitted to a single exponential decay curve
by non linear least square regression analysis. The estimated first-order rate
constant was used to calculate the mRNA half life.

cs

INS

PIO

INS+PIO

GLUT1
GLUT4

2.2
1.2

6.3

Adipsin

5.9

aP2

>24

4.1
24
>24
>24

> 24
>24
>24
>24

20.2
>24
>24

CHAPTERV
DISCUSSION

Hfect d insulin and pioglitaz.one on 3T3-F442A preadipocyte differentiation
Pioglitazone, 5-[4-(2-(5-ethyl-pyridyl)ethoxy)-benzoyl]-2,4-thiazolidinedione,
is an antidiabetic agent that has been shown to ameliorate hyperglycemia in
animal models of non-insulin-dependent diabetes mellitus (6, 145, 159).
Although a clear cut mode of action for pioglitazone has not been elucidated,
this agent appears to potentiate insulin action both in vivo and in vitro as
measured by enhanced insulin-stimulated glucose transport, suppressed
hypertriglyceridemia and hyperinsulinemia, but without increasing insulin
secretion (145,159). However, pioglitazone required the presence of insulin for
these effects and did not change insulin binding, thus suggesting that it might act
to amplify cellular responses to insulin. In fact, pioglitazone treatment was
shown to increase insulin-stimulated autophosphorylation of insulin receptors in
Wistar fatty rats (144), and to correct deficits in GLUT4 mRNA and protein in
fat and muscle of insulin deficient rats and KKA Y obese mice (6).
The purpose of my work was to further probe action mechanisms for
pioglitazone. Since adipose tissue functions as an energy reservoir wherein
glucose is used to synthesize triglycerides, treatment with agents such as
pioglitazone, which enhance glucose uptake, would be expected to be associated
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with changes in adipose tissue function and development. I thus decided to
investigate the effect of pioglitazone treatment on the differentiation of
preadipocytes to adipocytes as an indicator of adipose tissue development.
Such differentiated adipocytes are known to be fully active in glucose uptake,
storage, and metabolism. The results of this study clearly showed that the
antidiabetic agent pioglitazone acts as a potent accelerator of adipocyte
differentiation of 3T3-F442A cells. This was evidenced by the demonstration
that treatment of fibroblast-like cells with pioglitazone led to acquisition of the
morphological appearance of lipid-accumulating adipocytes with concomitant
increases in triglyceride accumulation. Both insulin and pioglitazone acted
synergistically on these parameters further supporting the notion that
pioglitazone acts to amplify cellular responses to insulin.
Although previous in vivo studies have shown the hypoglycemic effect of
pioglitazone to be dependent upon the presence of circulating insulin, my study
demonstrated effects of pioglitazone on cell differentiation without added
insulin. These two observations however, would become consistent when we
consider the fact that in my study differentiation was carried out in serumcontaining medium which is known to contain physiologically significant
concentrations of insulin. Therefore, under my experimental conditions,
pioglitazone might act to enhance cellular responses to low concentrations of
insulin.

Hfect d insulin and pioglitaznne on glucose transpoit activity and glucose
transpoiter gene expression
In the present study, I showed that the differentiation of 3T3-F442A cells
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with insulin and pioglitazone was accompanied by concomitant increases in
adipocyte basal glucose transport activity. Recent studies have established that
facilitated diffusion of glucose across the plasma membrane of adipose cells is
mediated by two glucose transporter proteins (105,106). Multiple mechanisms
may exist by which hormones and other factors control the rate of glucose
uptake across the plasma membrane. These include the rapid translocation of
pre-existing transporters from intracellular pool to the plasma membrane,
modulation of the intrinsic activity of pre-existing plasma membrane glucose
transporters, and stimulation of the synthesis of new transporters (12). My
results demonstrated increases in the expression of both GLUTl and GLUT4
transporters on mRNA and protein levels. These results are in agreement with
previous studies in which GLUTl and GLUT4 mRNA and protein levels were
shown to increase during differentiation of 3T3 preadipose cells (61, 108). The
increase in glucose transport activity in my study however, was at least an order
of magnitude higher than the combined increase in both transporter proteins
indicating that another mechanism such as increased transporter intrinsic
activity may contribute to the observed effect. This is not an unusual
observation since regulation of intrinsic transporter activity in 3T3-L 1
adipocytes has been previously reported (160, 161). Inhibition of protein
synthesis in 3T3-Ll adipocytes by anisomycin, for instance, appeared to
stimulate glucose transport primarily by enhancing the intrinsic catalytic activity
of cell surface GLUTl and to a lesser extent, GLUT4 proteins (161), while
tumor necrosis factor-a treatment reportedly increased glucose transport and

GLUTl transporter intrinsic activity in 3T3-Ll preadipose cells (160).
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Although adipocyte differentiation by insulin or pioglitazone increased the
expression of two transporter proteins and basal glucose uptake, no significant
increase in insulin-responsiveness of differentiated cells was observed in the
present study (data not shown). This could possibly be due to the chronic
exposure of cells to low concentrations of insulin in the serum during
differentiation, thus causing continuous translocation of existing, as well as
newly synthesized transporters, into the plasma membrane further contributing
to the high level of basal glucose uptake. Consequently, acute insulin exposure
does not induce further translocation normally known to be responsible for
enhanced acute insulin- responsiveness. Consistent with that mechanism are
two observations established by previous studies. First, chronic exposure of
differentiated 3T3-Ll adipocytes to insulin has been shown to result in
persistent state of enhanced basal glucose transport activity which was resistant
to further stimulation by insulin during hexose uptake assays (45), and second,
chronic insulin treatment of 3T3-F442A (108) and 3T3-Ll (62) adipocytes
induced a redistribution of glucose transporters in these cells from plasma
membrane to low density microsomes which was associated with marked
resistance of cells to restimulate glucose transport and particularly to recruit
GLUT4 to the cell surface following an additional insulin treatment (62). The
first study showed that chronic insulin treatment increased total cellular
GLUTl but did not change total cellular GLUT4 (45), while the latter study
showed that insulin resistance was associated with selective down-regulation of
cell-surface GLUT4 glucose transporter and particularly with a marked
resistance of cells to further recruit GLUT4 to the cell-surface following an
additional insulin treatment; while levels of GLUTl at the surface were
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markedly increased (62). These observations are in contrast with results
reported in another study in which insulin sensitivity was shown to increase
during differentiation of 3T3-L1 cells (61). In that study however, adipocyte
differentiation was induced by insulin, dexamethasone, and
isobutylmethylxanthine (IBMX), all of which are independently known to
regulate glucose transport and glucose transporter activity. Indeed, a similar
study showed that basal glucose uptake in 3T3-L 1 adipocytes was 50% lower
than that in fibroblasts which was due to more than 90% inhibition of the
intrinsic catalytic activity of GLUTl on the surface of mouse 3T3-L 1 adipocytes
(162). Therefore, a mechanism that markedly suppressed basal glucose
transport catalyzed by GLUTl was implicated as the major contributor to the
dramatic insulin sensitivity of glucose uptake in 3T3-L 1 adipocytes in these
studies. Thus, elevated basal glucose transport activity in my study would be
consistent with continuous translocation of existing, as well as newly
synthesized, GLUTl transporter into the cell-surface. In addition, changes in
intrinsic activity of cell-surface transporters would be speculated to account for
any discrepancy between increased GLUTl expression and increased basal
glucose uptake activity. Although there is an apparent contradiction between
increased GLUT4 expression and cell unresponsiveness, these two observations
are consistent with increased GLUT4 expression due to the differentiation of
preadipocytes to adipocytes, and with cell inability to recruit GLUT4 to the cellsurface due to the continuous exposure to insulin during differentiation.

Hfects d insulin and pioglitazone on adipocyte-specific gene expression
The present study indicated that the effect of insulin and pioglitazone on
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gene expression was not glucose transporter-specific since the abundance of
mRNAs encoding other adipocyte-specific genes were increased at the same
time, further confirming that pioglitazone has a general differentiation effect.
Adipsin and aP2 mRNAs for instance, were both increased by insulin or
pioglitazone treatments, in agreement with earlier studies in which these two
mRNA transcripts were shown to increase during adipocyte differentiation
(8, 10,85,92,99). No significant effect on insulin receptor gene expression was
detectable in my experiments under the same condition despite the fact that its
message and protein product have previously been reported to increase during
3T3-L 1 adipocyte differentiation (44,57,59,60, 102). The disparity between my
present results and those reported in previous studies could be due to the use of
different cell lines and/ or different differentiation conditions. In all these
studies, the 3T3-L1 preadipocyte/adipocyte cell line was used as a model
system. In addition, their differentiation medium variously contained
dexamethasone, IBMX, insulin, and indomethasone, all of which are known to
regulate adipocyte differentiation (44,57,59,60). My results also showed that
cell differentiation induced by a combination of insulin and pioglitazone
completely inhibited adipsin mRNA expression. Such results implicate some
negative mechanism contributing to the observed down-regulation effect on
adipsin and insulin receptor genes. In fact, prolonged insulin treatment has
previously been shown to downregulate insulin receptor protein and mRNA in
various tissues by accelerating its degradation and decreasing its biosynthesis
(58). Insulin was also shown to exert negative effect on the abundance of
adipsin mRNA in differentiating, as well as in fully differentiated 3T3-F442A
adipocytes via a mechanism which involved primarily a rapid inhibition of the
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transcriptional rate (73, 100, 163). Thus, it appears that insulin has both positive
effects due to its ability to accelerate differentiation, and negative effects due to
direct down-regulation at different pre-translational and/ or post-translational
levels, on insulin receptor and adipsin mRNAs. Indeed, my results
demonstrated that insulin and pioglitazone withdrawal after differentiation
relieved the negative down-regulating effect, thus revealing the differentiationdependent increases for these two mRNAs. The fact that insulin completely
down-regulated adipsin mRNA only in the presence of pioglitazone provides
additional evidence that pioglitazone acts to amplify cellular responses to
insulin.

Hfect d insulin and pioglitazone on transcription activity and mRNA stabi1ity
It has been previously established that alternations in the steady state level
of several mRNAs during differentiation were accompanied by activation of
specific gene transcription (8-10,75). This was particularly shown for mRNAs
whose abundance is dramatically increased (20- to 100-fold) during
differentiation, including the aP2 and glycerolphosphate dehydrogenase genes.
These same studies showed no significant change in the rates of transcription of
mRNAs whose abundance was only moderately altered (2- to 4-fold) during
differentiation, such as those encoding fructose-1,6-bisphosphate, B-actin, aactin, and B-tubulin (8). While transcriptional activation of adipsin gene
expression during 3T3-F442A differentiation was reported in one study (9),
another study failed to show such activation for this gene under similar
conditions (10). In these studies however, aP2 and adipsin mRNAs were found
to be far more abundant than would be predicted by their nuclear transcription
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alone, suggesting that other levels of control may contribute to the relative
abundance of these mRNAs. In my present study, run-on transcription by
nuclei isolated from undifferentiated 3T3-F442A cells or from cells
differentiated with insulin and/ or pioglitazone revealed little or no change in
the transcription activity for all studied genes. No transcription signal could be
detected for GLUT1 and GLUT4 mRNAs in either undifferentiated or
differentiated cells, although both mRNAs increased in abundance moderately
(2- to 6-fold) during differentiation. Transcription of adipsin and aP2 was
strongly detectable in undifferentiated cells, but no significant change in their
transcription activity could be detected upon differentiation despite the
dramatic increase (20- to 70-fold) in their steady state levels. There were two
exceptions. Insulin, in combination with pioglitazone, decreased the
transcription of adipsin mRNA, while pioglitazone moderately increased ( < 2fold) the transcription of aP2 mRNA. In all cases, the increase in the steady
state level of all studied mRNAs could not be explained by changes in their
corresponding transcription activities suggesting that other levels of control,
possibly mRNA stability, may contribute to the relative abundance of certain
mRNAs during adipocyte differentiation. To further investigate such a
possibility, I compared mRNA half lives in undifferentiated and differentiated
cells. Differentiation of 3T3-F442A cells by insulin and/ or pioglitazone
increased the mRNA half lives for GLUTl, GLUT4, and adipsin above their
values in undifferentiated cells. Furthermore, the stabilization of these mRNAs
caused by differentiation appears to fully account for the increase in their steady
state levels under most of the treatment conditions. There has been no
correlation, however, between the increase in adipsin mRNA half life and its
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steady state levels in the combined insulin and pioglitazone treatment. In this
case, the observed inhibition of gene transcription activity may account for the
extremely low abundance of adipsin mRNA. My results also failed to explain
the dramatic induction of aP2 gene expression upon differentiation, since its
mRNA was apparently very stable (half-life > 24 hr) in both undifferentiated
and differentiated cells. This could be due to several reasons. First, RNA
extracted from undifferentiated cells may has been contaminated with RNA
from a small number of spontaneously-differentiating cells in the same culture.
Thus, if aP2 gene expression is greatly enhanced very early in the process, My
results would falsely indicate very stable mRNA in undifferentiated cells.
Although I purposely used undifferentiated cultures before they reached
confluence, such spontaneous cell differentiation is still possible. Thus, further

in ·situ hybridization experiments would be required to confirm whether their is
an expression of aP2 gene in a minor population of spontaneously
differentiating fibroblast cells. An alternate possibility is that another posttranscriptional step, such as RNA processing contributes to the accumulation of
aP2 mRNA during differentiation. Since Northern blots showed only a single
aP2 mRNA species of the same size in both undifferentiated and differentiated
cells, such RNA processing would have to occur very early and extremely fast
during differentiation to explain our ability to detect a presumably processed
aP2 mRNA in undifferentiated cells. Another possibility is that aP2 mRNA is
stable in undifferentiated cells (half life > 24 hr) and it becomes more stable
with differentiation, but my results showed no measurable change in half life
because we carried out the stability study for only 24 hours. Measurements of
the aP2 mRNA half life, or that of any other adipocyte-specific mRNA, in
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undifferentiated preadipocytes have not been reported before because of the
extremely low abundance of the RNA in these cells. One study however,
reported aP2 mRNA half life in differentiated adipocytes and found it to be far
more stable in the adipocyte cytoplasm than other mRNAs examined, with an
estimated half life of 12 hours (10). Since that study did not show aP2 mRNA
half life in preadipocytes, it failed to indicate whether the apparent stability of
the aP2 is dependent on differentiation or whether it is an intrinsic property of
the RNA molecule. In either case, my results showed far more stable mRNA

( > 24 hr) than was reported which leads to another possibility. Actinomycin D
treatment has been shown specifically to stabilize certain mRNAs. For
instance, actinomycin D has been reported to have stabilizing effect on mRN As
for all protein kinase A subunits (164). Since aP2 mRNA half life in adipocytes
was reported to be 12 hours using 5,6-dichloro-1-.B-Dribofuranosylbenzimidazole (DRB) as a transcription inhibitor, the apparent
stability of aP2 mRNA in undifferentiated and differentiated cells in my study
could be due to a direct stabilizing effect on the aP2 gene by actinomycin D
treatment. This issue would be resolved in future studies by using a different
transcription inhibitor such as DRB, or thiolutin, or using a different method
such as [3H]uridine-chase method to assess message stability.
Taken together, my results indicate that the mechanism underlying
differentiation-dependent changes in mRNA abundance induced by insulin or
pioglitazone appears to be mostly on the level of mRNA stability rather than
transcriptional activation. Although this is the first study that directly shows
increased mRNA abundance during differentiation by increasing message
stability, such mechanism of regulation at mRNA stability level has been
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reported under various conditions. Treatment of 3T3-F442A mature adipocytes
with retinoic acid for instance, specifically decreased the adipsin mRNA level
(165). The rate of adipsin gene transcription remained unchanged, while the
half life of adipsin mRNA was greatly shortened in retinoic acid-treated
adipocytes (37.6 to 7.3 hr) as compared with untreated cells. Another example
is the induction of GLUTl, as well as other immediate early growth related
protooncogenes, in 3T3-Ll fibroblasts by treatment with tumor necrosis factora (160,166) and 8-bromo-cAMP (167). While transcriptional activation of
immediate-early genes correlated well with subsequent accumulation of their
respective mRNAs, increased GLUTl mRNA was due to apparent increase in
the stability of this message (45 min to several hours) and not to increased
transcription. Another study showed that increased GLUTl mRNA abundance
by chronic exposure of L6 myocytes to insulin was due to increased transcription
as well as prolonged half life (2-2.5 hr to 5 hr) (168).

Signfficance and future studies

My findings demonstrated that pioglitazone, like insulin, has the ability to
accelerate the in vitro adipocyte differentiation of 3T3-F442A cells with
concomitant increases in the expression of two glucose transporter genes. This
finding is consistent with a recent report of pioglitazone having adipogenic
activity in 3T3-Ll cell line (169). This is the second example of an antidiabetic
agent with adipogenic activity. A recent study demonstrated that another
antidiabetic agent with similar thiazolidinedione derived structure, AD4 743,
enhanced adipocyte differentiation of 3T3 T mesenchymal stem cells (77).
Although not established in vivo, this would constitute an interesting mechanism
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of action for hypoglycemic agents by enhancing insulin sensitivity of target
tissues, thus correcting blood glucose levels in diabetes. Therefore, the effect of
pioglitazone on adipocyte differentiation from stromal vascular cells (the in vivo
adipocyte progenitor cell) should be investigated and characterized in future
experiments to establish the pertinence of such an effect to its in vivo
hypoglycemic activity. The observations that pioglitazone acted synergistically
with insulin on adipocyte differentiation and on glucose transport activity
provide additional support to the concept that pioglitazone acts to amplify
cellular responses to insulin, but do not prove it. Since cell differentiation was
carried out in the presence of serum, I was not able to ascertain whether
pioglitazone induced effects on cell differentiation and glucose transport activity
were dependent on the presence of insulin in the serum or not. Thus, it is
necessary to develop a defined serum-free differentiation medium in order to
determine the role of each of insulin and pioglitazone individually and how they
interact with each other to regulate adipocyte differentiation and glucose
transport activity.
Pioglitazone also showed direct transcriptional activation effect on the aP2
gene. Considering the fact that aP2 mRNA is expressed at high levels in
adipocytes (87), and that it has a postulated role as a mediator of insulin actions
(89), aP2 presents an interesting candidate gene for further exploration of
insulin action mechanisms, their perturbations in diabetes, and possible
corrective effects of pioglitazone treatment.
My findings have interesting implications for better understanding the
processes involved in cellular differentiation and development. This is the first
report directly showing increased abundance of adipocyte-specific mRNA
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during differentiation as result of increasing message stability, although the
concept was previously inferred (8-10). The stabilization or destabilization of
mRN As in response to some biological or pharmacological stimuli has been
recognized as an important post-transcriptional step in the regulation of gene
expression (170-173). Despite that, the mechanism underlying such processes,
including the signals that trigger mRNA degradation, the structural elements of
an individual mRNA recognized by the degradative enzymes, as well as the
enzymes and other trans-acting factors that are involved in mRNA degradation,
remain largely unknown (170,173-176).
Recent studies demonstrated that some mRNA sequences may play
important role in determining degradation rates. Of particular importance are
the 3' terminal untranslated region (UTR) and poly(A) sequences (174). The
rate of mRNA degradation was shown to be dependent on the presence or
absence of the 3' terminal poly(A), and that the de-adenylated mRNA
apparently had a faster rate of turnover ( 170, 177, 178).
Although not studied within the context of differentiation, there is some
evidence that adipsin and GLUTl mRNAs are regulated through effects on
their 3' -UTR sequences. A recent study has shown that within a physiological
range of concentrations, insulin exerts a negative effect on adipsin mRNA
abundance in 3T3-F442A adipocytes, which was found to involve a rapid
inhibition of the transcriptional rate (163). At the same time, insulin showed a
specific effect on the length of the poly(A) tract of the adipsin mRNA. The
study did not show the consequence of decreasing the adipsin poly(A) tract
length, but speculated that it could affect translational efficiency or the stability
of mRNA. Indeed, upon examining my Northern blots carefully, both GLUTl
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and adipsin mRNAs appeared as broad signals in differentiated cells. Such
heterogeneity in mRNA length could be speculated to be the result of variation
of the poly(A) tract length which would be consistent with the previously cited
study (163). Further experiments using RNase H digestion of mRNA would be
required to prove such a possibility.
Another study showed that tumor necrosis factor-a stimulated hexose
transport in quiescent 3T3-Ll preadipocytes by stabilizing the relatively labile
mRNA coding for the basal glucose transporter, GLUTl (166). The 3'-UTR of
GLUTl mRNA contains a single copy of the destabilizing AUUUA motif in the
context of an AU-rich region. The stability of GLUTl mRNA was found to be
partially controlled by its interaction with sequence-specific mRNA binding
protein, the adenosine-uridine binding factor (AUBF), which was speculated to
mediate mRNA stabilization by blocking the AU-destabilizing motifs. Further
sequence analysis of the 3' -UTR of other adipocyte-specific genes is required to
identify putative cis'-elements through which such regulation might occur.
Thus, increasing mRNA abundance during differentiation by increasing
message stability presents an interesting phenomenon awaiting further probing
with regard to the differentiation and development fields. Future efforts should
be particularly directed towards identifying common mRNA sequences that may
function as stabilizing elements in the differentiation-induced mRNAs, and the
potential regulatory mRNA binding proteins that are upregulated in response to
various differentiation-inducing factors.
Overall, this study of pioglitazone effects in a cell culture system should
prove to be a useful model with which to study molecular mechanisms
underlying cell differentiation as well as insulin action on glucose transport.
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